fluoxetine has been researched along with Obsessive-Compulsive Disorder in 400 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Obsessive-Compulsive Disorder: An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since it will be some time until data will be available comparing clomipramine and fluoxetine for the treatment of patients with obsessive-compulsive disorder (OCD), a meta-analysis of previous studies was performed in an attempt to gain some information about comparable efficacy and side effects of these two commonly used agents." | 10.16 | Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy. ( Baer, L; Greist, JH; Jenike, MA, 1990) |
| "Thirty-eight patients with primary obsessive-compulsive disorder participated in a 10-week, double-blind, placebo-controlled trial of the potent, selective serotonin reuptake inhibitor fluvoxamine." | 10.16 | A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. ( Baer, L; Buttolph, L; Holland, A; Hyman, S; Jenike, MA; Minichiello, WE; Ricciardi, J; Seymour, R; Summergrad, P, 1990) |
| "To determine the efficacy of fluoxetine for reducing the frequency and severity of obsessive-compulsive behaviors in autism spectrum disorders." | 9.30 | Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial. ( Dossetor, D; Granich, J; Hazell, P; Kohn, M; Lee, KJ; Marraffa, C; Mouti, A; O'Sullivan, M; Orsini, F; Reddihough, DS; Santosh, P; Silove, N; Whitehouse, AJO; Wray, J, 2019) |
| "Several controlled trials have demonstrated the efficacy and safety of Fluoxetine in children and adolescents with Obsessive-Compulsive Disorder (OCD), but there is no controlled study on the effectiveness of Citalopram in this group." | 9.14 | A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD). ( Alaghband-Rad, J; Hakimshooshtary, M, 2009) |
| "To assess the efficacy and tolerability of ondansetron in combination with selective serotonin reuptake inhibitors (SSRIs) in patients with obsessive-compulsive disorder (OCD)." | 9.14 | A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. ( Feizy, F; Malayeri, A; Motlagh, I; Sayyah, M; Siahpoosh, A; Soltani, F, 2010) |
| "The purpose of this study was to evaluate the comparative efficacy and tolerability of sertraline and fluoxetine in the treatment of obsessive-compulsive disorder (OCD)." | 9.10 | Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study. ( Austin, C; Bergeron, R; Chaput, Y; Goldner, E; Hadrava, V; Ravindran, AV; Swinson, R; van Ameringen, MA, 2002) |
| "Adding the atypical neuroleptic risperidone to a serotonin reuptake inhibitor (SRI) has benefited patients with treatment-refractory obsessive-compulsive disorder (OCD)." | 9.09 | Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. ( Elliott, MA; Koran, LM; Ringold, AL, 2000) |
| "This study assesses the efficacy and tolerability of fluoxetine in the acute treatment of child and adolescent obsessive-compulsive disorder (OCD) during a 13-week, double-blind, placebo-controlled study." | 9.09 | Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. ( Geller, DA; Heiligenstein, JH; Hoog, SL; Jacobson, JG; Kluszynski, S; Ricardi, RK; Tamura, R, 2001) |
| "The circadian rhythms of melatonin and cortisol were evaluated in seven outpatients with obsessive-compulsive disorder (OCD) before and after 8 weeks of fluoxetine treatment (20 mg/day in the first 2 weeks, and 40 mg/day afterwards), and in seven healthy subjects matched to patients on age, sex and season of testing." | 9.08 | Plasma melatonin and cortisol circadian patterns in patients with obsessive-compulsive disorder before and after fluoxetine treatment. ( Catapano, F; Di Martino, S; Maj, M; Monteleone, P; Tortorella, A, 1995) |
| "Ratings of symptom severity of obsessive-compulsive disorder (Yale-Brown Obsessive Compulsive Scale scores) were obtained at baseline and after 13 weeks for 200 adult outpatients with moderately severe obsessive-compulsive disorder treated with fluoxetine doses of 20 mg/day (N = 68), 40 mg/day (N = 64), and 60 mg/day (N = 68)." | 9.08 | Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? ( Cain, JW; Dominguez, RA; Koran, LM; Rush, AJ; Thiemann, S, 1996) |
| "Eight subjects with DSM-IV obsessive-compulsive disorder were entered into a prospective, open-label treatment trial of fluvoxamine." | 9.08 | 19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. ( Dager, SR; Hayes, CE; Layton, ME; Strauss, WL, 1997) |
| "It is now well documented that fluoxetine is a viable treatment option for patients with obsessive-compulsive disorder (OCD), and there is a small body of evidence indicating that monoamine oxidase inhibitors may be effective in at least a subset of patients." | 9.08 | Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. ( Baer, L; Buttolph, ML; Jenike, MA; Minichiello, WE; Rauch, SL, 1997) |
| "In a double-blind study, desipramine or placebo was added for 6 or 10 weeks to the treatment of 30 patients with obsessive-compulsive disorder whose symptoms were refractory to SSRI treatment (fluvoxamine, fluoxetine, or sertraline) alone." | 9.08 | Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. ( Anand, A; Barr, LC; Goodman, WK; McDougle, CJ; Price, LH, 1997) |
| "The authors conducted a randomized, placebo-controlled, double-blind, 7-week study of fluoxetine at a target daily dose of 60 mg in 31 women with anorexia nervosa receiving treatment for their eating disorder on a clinical research unit." | 9.08 | Does fluoxetine augment the inpatient treatment of anorexia nervosa? ( Attia, E; Flater, SR; Haiman, C; Walsh, BT, 1998) |
| "Fluoxetine is effective in treating obsessive-compulsive disorder (OCD)." | 9.08 | Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder. ( Ackerman, DL; Bystritsky, A; Greenland, S, 1998) |
| "The aim of the study was to assess the efficacy and tolerability of fluoxetine treatment of acral lick dermatitis (ALD) in dogs and to investigate ALD as an animal model of obsessive-compulsive disorder (OCD)." | 9.08 | Fluoxetine treatment of acral lick dermatitis in dogs: a placebo-controlled randomized double blind trial. ( Berk, M; Wynchank, D, 1998) |
| "To determine the effectiveness of fluoxetine hydrochloride at fixed doses of 20 mg/d, 40 mg/d, and 60 mg/d in patients with obsessive-compulsive disorder (OCD) and to evaluate its safety." | 9.07 | A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. ( Genduso, LA; Goodman, W; Jenike, MA; kominguez, RA; Koran, LM; Potvin, JH; Rampey, AH; Rush, AJ; Shear, MK; Tollefson, GD, 1994) |
| "We have studied the effect of three fixed daily doses of fluoxetine in patients with obsessive-compulsive disorder (OCD) diagnosed according to DSM-III-R." | 9.07 | A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. ( Birkett, M; McIntyre, A; Montgomery, SA; Osterheider, M; Sarteschi, P; Wood, AJ; Zitterl, W; Zohar, J, 1993) |
| "In a double-blind, crossover study, 13 fluoxetine-treated patients with obsessive-compulsive disorder were given adjuvant buspirone and placebo for 4 weeks each." | 9.07 | Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. ( Bernstein, SE; Grady, TA; Hill, JL; L'Heureux, F; Murphy, DL; Pigott, TA, 1993) |
| "Rigorously designed clinical trials have demonstrated the efficacy and safety of fluoxetine in adults with major depressive disorder and obsessive-compulsive disorder (OCD) but not in patients below 18 years old." | 9.07 | Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. ( Anderson, GM; Cohen, DJ; Hardin, MT; King, RA; Leckman, JF; Ort, SI; Riddle, MA; Scahill, L; Smith, JC, 1992) |
| "Since (a) obsessive-compulsive disorder (OCD) may involve serotonergic neural transmission abnormalities also though to be related to regulation of suicide and aggression, (b) comorbidity between OCD and depression is substantial, and (c) depression is a major risk factor for suicide, a comprehensive analysis of clinical trial data was undertaken to assess the potential association of fluoxetine, a serotonin uptake inhibitor, and suicidality (suicidal acts and ideation)." | 9.07 | Fluoxetine: no association with suicidality in obsessive-compulsive disorder. ( Beasley, CM; Dornseif, BE; Genduso, LA; Masica, DN; Potvin, JH; Wheadon, DE, 1992) |
| "Fluoxetine (FLX) is a selective serotonin (5-HT) reuptake inhibitor with therapeutic benefit in patients with obsessive-compulsive disorder (OCD)." | 9.07 | Long-term fluoxetine treatment decreases 5-HT1A receptor responsivity in obsessive-compulsive disorder. ( Hoh, A; Lesch, KP; Müller, T; Osterheider, M; Schulte, HM, 1991) |
| "At the time of follow-up (11 +/- 6 months on fluoxetine), 29 of the 31 patients had maintained their weight at or above 85% average body weight (97% +/- 13% average body weight for the group)." | 9.07 | An open trial of fluoxetine in patients with anorexia nervosa. ( Bulik, CM; Hsu, LK; Kaye, WH; Weltzin, TE, 1991) |
| "To investigate the effect of fluoxetine on serotonergic sensitivity in obsessive-compulsive disorder (OCD), the partial serotonin agonist metachlorophenylpiperazine (mCPP) was compared to placebo under double-blind conditions in six patients with OCD before and during treatment with fluoxetine." | 9.07 | Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. ( DeCaria, C; Gorman, JM; Gully, R; Hollander, E; Klein, DF; Liebowitz, MR; Nitescu, A; Suckow, RF, 1991) |
| "Treatment with fluoxetine hydrochloride was compared with treatment with clomipramine hydrochloride in two groups of patients with obsessive-compulsive disorder using two different experimental designs." | 9.06 | Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results. ( Bernstein, SE; Grover, GN; Hill, JL; Murphy, DL; Pato, MT; Pigott, TA; Tolliver, TJ, 1990) |
| "Clomipramine has been reported to be effective in the treatment of obsessive-compulsive disorder (OCD)." | 9.06 | Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination. ( Simeon, JG; Thatte, S; Wiggins, D, 1990) |
| "The selective serotonin reuptake blocker fluoxetine was administered to 49 patients with obsessive-compulsive disorder in a 12-week open clinical trial." | 9.06 | Fluoxetine treatment of obsessive-compulsive disorder: an open clinical trial. ( Campeas, R; Davies, S; Fairbanks, J; Hatterer, J; Hollander, E; Liebowitz, MR; Papp, L; Sandberg, D; Schneier, F; Stein, M, 1989) |
| "In a 9-week open label study, seven outpatients with obsessive-compulsive disorder were treated with fluoxetine, a selective inhibitor of neuronal reuptake of serotonin." | 9.06 | An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder. ( Chouinard, G; Fontaine, R, 1986) |
| "This meta-analysis assessed aggression and/or hostility-related events in children and adolescents treated with fluoxetine (n = 376) compared with placebo (n = 255)." | 8.84 | Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placebo. ( Allen, AJ; Caldwell, C; Nilsson, M; Plewes, J; Tauscher-Wisniewski, S, 2007) |
| "The most common effective treatments for obsessive-compulsive disorder include clomipramine, fluoxetine, and exposure-based behavior therapy." | 8.78 | Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: a meta-analysis. ( Cox, BJ; Lee, PS; Morrison, B; Swinson, RP, 1993) |
| "We report a case of an 18-year-old, middle-eastern female patient who developed onychotillomania when she was being treated with paroxetine for obsessive-compulsive disorder and was showing partial improvement." | 8.12 | Fluoxetine for the treatment of onychotillomania associated with obsessive-compulsive disorder: a case report. ( Aljhani, S, 2022) |
| "The principal aim of the current study was to check the potential contribution of repurposing of magic shotgun nature of curcumin (rhizomes of Curcuma longa) with scattergun approach- proceeding a pioneer 'fine-tune' for obsessive-compulsive disorder." | 8.02 | Magic Shotgun Nature with Scattergun Approach of Curcumin Repurposing in Obsessive-compulsive Disorder: A Novel Metaphysician of Drug Discovery. ( Gupta, A; Mishra, A; Mishra, RK, 2021) |
| "The aim of this study was to investigate the efficacy and safety of fluoxetine in the treatment of obsessive-compulsive disorder (OCD) in preschool children." | 7.75 | Efficacy and safety of fluoxetine in preschool children with obsessive-compulsive disorder. ( Coskun, M; Zoroglu, S, 2009) |
| "Consecutive outpatients with obsessive-compulsive disorder were evaluated for response to a two-month fluoxetine therapy course by Yale-Brown obsessive-compulsive scale according to the clinical subtype of the disease." | 7.74 | Effectiveness of fluoxetine on various subtypes of obsessive-compulsive disorder. ( Farhang, S; Farnam, A; Goreishizadeh, MA, 2008) |
| " We therefore describe an adolescent sex offender who met DSM-IV criteria for multiple paraphilias (except for the age criterion), bipolar type II disorder, and OCD, whose paraphilic urges and behaviors, depression, and violent obsessions responded to open label fluoxetine after failing to respond to long-term residential treatment." | 7.70 | An adolescent male with multiple paraphilias successfully treated with fluoxetine. ( Galli, VB; McConville, BJ; McElroy, SL; Raute, NJ, 1998) |
| "Clomipramine appeared much more effective and better tolerated than fluoxetine in this very old patient despite its potential anticholinergic effect and the coexistence of Alzheimer disease." | 7.70 | Treatment of obsessive-compulsive disorder using clomipramine in a very old patient. ( Trappler, B, 1999) |
| " We report a case of a possible interaction with pimozide which led to a potentially life threatening bradycardia." | 7.68 | Possible interaction between fluoxetine and pimozide causing sinus bradycardia. ( Ahmed, I; Dagincourt, PG; Miller, LG; Shader, RI, 1993) |
| "An open trial of pharmacological treatment with fluoxetine, ranging from 20 mg every other day to 80 mg per day, led to a significant improvement in Clinical Global Impressions ratings of Clinical Severity in 15 of 23 subjects with autistic disorder and 10 of 16 subjects with mental retardation." | 7.68 | Fluoxetine treatment of children and adults with autistic disorder and mental retardation. ( Cook, EH; Jaselskis, C; Leventhal, BL; Rowlett, R, 1992) |
| "Two patients suffering from severe obsessive-compulsive disorder which had proven refractory to clomipramine and/or phenelzine treatment were successfully treated with fluoxetine, a new drug with a strong serotonin uptake inhibiting action." | 7.68 | Fluoxetine treatment of obsessive-compulsive disorder. ( Ledwidge, B; Solyom, C; Solyom, L, 1991) |
| "Ten outpatients meeting DSM-III-R criteria for obsessive-compulsive disorder completed a 32-week, open-label study with fluoxetine, a selective serotonin reuptake blocker." | 7.68 | Efficacy of long-term fluoxetine treatment of obsessive-compulsive disorder. ( Frenkel, A; Nezu, A; Rosenthal, J; Winston, A, 1990) |
| "A 12-week open trial of fluoxetine in 61 obsessive-compulsive disorder patients significantly improved depressive and obsessive-compulsive symptoms." | 7.67 | Open trial of fluoxetine in obsessive-compulsive disorder. ( Baer, L; Buttolph, L; Holland, A; Jenike, MA; Ricciardi, J, 1989) |
| " Adverse events were also assessed." | 6.94 | The safety and efficacy of transcranial direct current stimulation as add-on therapy to fluoxetine in obsessive-compulsive disorder: a randomized, double-blind, sham-controlled, clinical trial. ( Amanat, M; Behzadmanesh, J; Mousavi, SV; Safary, V; Salehi, B; Salehi, M; Yoonesi, A; Yoosefee, S, 2020) |
| "Fluoxetine (FLX) has been one of the most widely studied selective serotonin reuptake inhibitors in adolescents." | 6.79 | Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder. ( Arnaiz, JA; Blázquez, A; Gassó, P; Lafuente, A; Lázaro, L; Mas, S; Méndez, I; Plana, MT; Torra, M, 2014) |
| "" These behaviors emerged despite gradual dose elevation (2-5 mg/wk), conservative dosing (maximum 40 mg daily), and careful weekly outpatient monitoring of each patient." | 6.69 | Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder. ( Birmaher, B; Go, FS; Malley, EE; Rosenberg, DR, 1998) |
| "Metergoline levels were higher in fluoxetine-treated patients." | 6.69 | Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients. ( Altemus, M; Benjamin, J; Greenberg, BD; Huang, SJ; Keuler, D; Martin, JD; Murphy, DL, 1998) |
| " The dosage of FLX was fixed at either 20, 40, or 60 mg per day." | 6.69 | Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder. ( Dossenbach, M; Hornik, K; Meszaros, K; Twaroch, T; Zapotoczky, HG; Zitterl, W; Zitterl-Eglseer, K, 1999) |
| "In general, effective treatments for trichotillomania have been elusive." | 6.67 | Clinical characteristics of trichotillomania and its response to fluoxetine. ( Jones, JS; Molcho, A; Stanley, B; Stanley, M; Winchel, RM, 1992) |
| "To examine the efficacy and tolerability of clomipramine compared with the selective serotonin reuptake inhibitors (SSRIs) in the treatment of obsessive-compulsive disorder (OCD), bearing in mind the recent Expert Consensus Guidelines recommendation to use clomipramine after 2 to 3 failed SSRI trials." | 6.19 | On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible? ( Borgeat, F; Freeston, MH; Todorov, C, 2000) |
| "Since it will be some time until data will be available comparing clomipramine and fluoxetine for the treatment of patients with obsessive-compulsive disorder (OCD), a meta-analysis of previous studies was performed in an attempt to gain some information about comparable efficacy and side effects of these two commonly used agents." | 6.16 | Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy. ( Baer, L; Greist, JH; Jenike, MA, 1990) |
| "Thirty-eight patients with primary obsessive-compulsive disorder participated in a 10-week, double-blind, placebo-controlled trial of the potent, selective serotonin reuptake inhibitor fluvoxamine." | 6.16 | A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. ( Baer, L; Buttolph, L; Holland, A; Hyman, S; Jenike, MA; Minichiello, WE; Ricciardi, J; Seymour, R; Summergrad, P, 1990) |
| "Developmental stuttering and tics share many clinical and therapeutical aspects." | 5.34 | Severe stuttering and motor tics responsive to cocaine. ( Linazasoro, G; Van Blercom, N, 2007) |
| "To determine the efficacy of fluoxetine for reducing the frequency and severity of obsessive-compulsive behaviors in autism spectrum disorders." | 5.30 | Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial. ( Dossetor, D; Granich, J; Hazell, P; Kohn, M; Lee, KJ; Marraffa, C; Mouti, A; O'Sullivan, M; Orsini, F; Reddihough, DS; Santosh, P; Silove, N; Whitehouse, AJO; Wray, J, 2019) |
| "Clinical effectiveness of group cognitive-behavioral therapy (GCBT) versus fluoxetine in obsessive-compulsive disorder outpatients that could present additional psychiatric comorbidities was assessed." | 5.16 | Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial. ( Belotto-Silva, C; Borcato, S; Diniz, JB; Fossaluza, V; Malavazzi, DM; Miguel, EC; Morelli, D; Seixas, AA; Shavitt, RG; Valério, C, 2012) |
| "To identify neuropsychological predictors of treatment response to cognitive-behavioral therapy (CBT) and fluoxetine in treatment-naïve adults with obsessive-compulsive disorder (OCD)." | 5.16 | Neuropsychological predictors of response to randomized treatment in obsessive-compulsive disorder. ( Batistuzzo, MC; D'Alcante, CC; Deckersbach, T; Diniz, JB; Fossaluza, V; Hoexter, MQ; Lopes, AC; Malloy-Diniz, L; Miguel, EC; Shavitt, RG, 2012) |
| "Several controlled trials have demonstrated the efficacy and safety of Fluoxetine in children and adolescents with Obsessive-Compulsive Disorder (OCD), but there is no controlled study on the effectiveness of Citalopram in this group." | 5.14 | A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD). ( Alaghband-Rad, J; Hakimshooshtary, M, 2009) |
| "To assess the efficacy and tolerability of ondansetron in combination with selective serotonin reuptake inhibitors (SSRIs) in patients with obsessive-compulsive disorder (OCD)." | 5.14 | A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. ( Feizy, F; Malayeri, A; Motlagh, I; Sayyah, M; Siahpoosh, A; Soltani, F, 2010) |
| "To examine the safety and efficacy of fluoxetine in child and adolescent obsessive-compulsive disorder (OCD)." | 5.10 | Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. ( Beidel, DC; Clarvit, SR; Davies, SO; Graae, F; Jaffer, M; Liebowitz, MR; Lin, SH; Piacentini, J; Sallee, FR; Schmidt, AB; Simpson, HB; Turner, SM, 2002) |
| "The purpose of this study was to evaluate the comparative efficacy and tolerability of sertraline and fluoxetine in the treatment of obsessive-compulsive disorder (OCD)." | 5.10 | Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study. ( Austin, C; Bergeron, R; Chaput, Y; Goldner, E; Hadrava, V; Ravindran, AV; Swinson, R; van Ameringen, MA, 2002) |
| "Differences between the side effect profiles of clomipramine (CMI) and the selective serotonin reuptake inhibitors may be important factors in both treatment outcome and patient selection in obsessive-compulsive disorder (OCD)." | 5.09 | Side effects as predictors of drug response in obsessive-compulsive disorder. ( Ackerman, DL; Bystritsky, A; Greenland, S, 1999) |
| "Adding the atypical neuroleptic risperidone to a serotonin reuptake inhibitor (SRI) has benefited patients with treatment-refractory obsessive-compulsive disorder (OCD)." | 5.09 | Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. ( Elliott, MA; Koran, LM; Ringold, AL, 2000) |
| "This study assesses the efficacy and tolerability of fluoxetine in the acute treatment of child and adolescent obsessive-compulsive disorder (OCD) during a 13-week, double-blind, placebo-controlled study." | 5.09 | Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. ( Geller, DA; Heiligenstein, JH; Hoog, SL; Jacobson, JG; Kluszynski, S; Ricardi, RK; Tamura, R, 2001) |
| "There is evidence of the clinical efficacy and safety of clomipramine and the newer selective serotonin reuptake inhibitors (SSRIs) for the treatment of obsessive-compulsive disorder (OCD)." | 5.08 | Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. ( Bourgeois, M; Cottraux, J; Gómez-Pérez, JC; Hernández, M; López-Ibor, JJ; Note, I; Saiz, J; Viñas, R, 1996) |
| "The circadian rhythms of melatonin and cortisol were evaluated in seven outpatients with obsessive-compulsive disorder (OCD) before and after 8 weeks of fluoxetine treatment (20 mg/day in the first 2 weeks, and 40 mg/day afterwards), and in seven healthy subjects matched to patients on age, sex and season of testing." | 5.08 | Plasma melatonin and cortisol circadian patterns in patients with obsessive-compulsive disorder before and after fluoxetine treatment. ( Catapano, F; Di Martino, S; Maj, M; Monteleone, P; Tortorella, A, 1995) |
| "Ratings of symptom severity of obsessive-compulsive disorder (Yale-Brown Obsessive Compulsive Scale scores) were obtained at baseline and after 13 weeks for 200 adult outpatients with moderately severe obsessive-compulsive disorder treated with fluoxetine doses of 20 mg/day (N = 68), 40 mg/day (N = 64), and 60 mg/day (N = 68)." | 5.08 | Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? ( Cain, JW; Dominguez, RA; Koran, LM; Rush, AJ; Thiemann, S, 1996) |
| "Eight subjects with DSM-IV obsessive-compulsive disorder were entered into a prospective, open-label treatment trial of fluvoxamine." | 5.08 | 19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. ( Dager, SR; Hayes, CE; Layton, ME; Strauss, WL, 1997) |
| "It is now well documented that fluoxetine is a viable treatment option for patients with obsessive-compulsive disorder (OCD), and there is a small body of evidence indicating that monoamine oxidase inhibitors may be effective in at least a subset of patients." | 5.08 | Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. ( Baer, L; Buttolph, ML; Jenike, MA; Minichiello, WE; Rauch, SL, 1997) |
| "In a double-blind study, desipramine or placebo was added for 6 or 10 weeks to the treatment of 30 patients with obsessive-compulsive disorder whose symptoms were refractory to SSRI treatment (fluvoxamine, fluoxetine, or sertraline) alone." | 5.08 | Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. ( Anand, A; Barr, LC; Goodman, WK; McDougle, CJ; Price, LH, 1997) |
| "The authors conducted a randomized, placebo-controlled, double-blind, 7-week study of fluoxetine at a target daily dose of 60 mg in 31 women with anorexia nervosa receiving treatment for their eating disorder on a clinical research unit." | 5.08 | Does fluoxetine augment the inpatient treatment of anorexia nervosa? ( Attia, E; Flater, SR; Haiman, C; Walsh, BT, 1998) |
| "Fluoxetine is effective in treating obsessive-compulsive disorder (OCD)." | 5.08 | Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder. ( Ackerman, DL; Bystritsky, A; Greenland, S, 1998) |
| "The aim of the study was to assess the efficacy and tolerability of fluoxetine treatment of acral lick dermatitis (ALD) in dogs and to investigate ALD as an animal model of obsessive-compulsive disorder (OCD)." | 5.08 | Fluoxetine treatment of acral lick dermatitis in dogs: a placebo-controlled randomized double blind trial. ( Berk, M; Wynchank, D, 1998) |
| " By the response of the patients to alprazolam (anxiolytic) and fluoketin (antidepressant) given by a special scheme, 3 types of comorbidity of obsessional-phobic and affective disturbances were recognized: 1) prevalent depression, 2) combination of dysthymia with marked obsessional-phobic disorders, 3) overcoming of obsessional-phobic and affective disorders." | 5.07 | [The psychopharmacotherapy of anxious-depressive states (the interrelationship of the structure of the comorbidity to the choice of drug therapy)]. ( Andriushchenko, AV; Koliutskaia, EV; Morkovkina, IV; Smulevich, AB; Tkhostov, ASh, 1994) |
| "To determine the effectiveness of fluoxetine hydrochloride at fixed doses of 20 mg/d, 40 mg/d, and 60 mg/d in patients with obsessive-compulsive disorder (OCD) and to evaluate its safety." | 5.07 | A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. ( Genduso, LA; Goodman, W; Jenike, MA; kominguez, RA; Koran, LM; Potvin, JH; Rampey, AH; Rush, AJ; Shear, MK; Tollefson, GD, 1994) |
| "We have studied the effect of three fixed daily doses of fluoxetine in patients with obsessive-compulsive disorder (OCD) diagnosed according to DSM-III-R." | 5.07 | A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. ( Birkett, M; McIntyre, A; Montgomery, SA; Osterheider, M; Sarteschi, P; Wood, AJ; Zitterl, W; Zohar, J, 1993) |
| "In a double-blind, crossover study, 13 fluoxetine-treated patients with obsessive-compulsive disorder were given adjuvant buspirone and placebo for 4 weeks each." | 5.07 | Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. ( Bernstein, SE; Grady, TA; Hill, JL; L'Heureux, F; Murphy, DL; Pigott, TA, 1993) |
| "Rigorously designed clinical trials have demonstrated the efficacy and safety of fluoxetine in adults with major depressive disorder and obsessive-compulsive disorder (OCD) but not in patients below 18 years old." | 5.07 | Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. ( Anderson, GM; Cohen, DJ; Hardin, MT; King, RA; Leckman, JF; Ort, SI; Riddle, MA; Scahill, L; Smith, JC, 1992) |
| "Since (a) obsessive-compulsive disorder (OCD) may involve serotonergic neural transmission abnormalities also though to be related to regulation of suicide and aggression, (b) comorbidity between OCD and depression is substantial, and (c) depression is a major risk factor for suicide, a comprehensive analysis of clinical trial data was undertaken to assess the potential association of fluoxetine, a serotonin uptake inhibitor, and suicidality (suicidal acts and ideation)." | 5.07 | Fluoxetine: no association with suicidality in obsessive-compulsive disorder. ( Beasley, CM; Dornseif, BE; Genduso, LA; Masica, DN; Potvin, JH; Wheadon, DE, 1992) |
| "Fluoxetine (FLX) is a selective serotonin (5-HT) reuptake inhibitor with therapeutic benefit in patients with obsessive-compulsive disorder (OCD)." | 5.07 | Long-term fluoxetine treatment decreases 5-HT1A receptor responsivity in obsessive-compulsive disorder. ( Hoh, A; Lesch, KP; Müller, T; Osterheider, M; Schulte, HM, 1991) |
| "At the time of follow-up (11 +/- 6 months on fluoxetine), 29 of the 31 patients had maintained their weight at or above 85% average body weight (97% +/- 13% average body weight for the group)." | 5.07 | An open trial of fluoxetine in patients with anorexia nervosa. ( Bulik, CM; Hsu, LK; Kaye, WH; Weltzin, TE, 1991) |
| "To investigate the effect of fluoxetine on serotonergic sensitivity in obsessive-compulsive disorder (OCD), the partial serotonin agonist metachlorophenylpiperazine (mCPP) was compared to placebo under double-blind conditions in six patients with OCD before and during treatment with fluoxetine." | 5.07 | Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. ( DeCaria, C; Gorman, JM; Gully, R; Hollander, E; Klein, DF; Liebowitz, MR; Nitescu, A; Suckow, RF, 1991) |
| "Treatment with fluoxetine hydrochloride was compared with treatment with clomipramine hydrochloride in two groups of patients with obsessive-compulsive disorder using two different experimental designs." | 5.06 | Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results. ( Bernstein, SE; Grover, GN; Hill, JL; Murphy, DL; Pato, MT; Pigott, TA; Tolliver, TJ, 1990) |
| "Clomipramine has been reported to be effective in the treatment of obsessive-compulsive disorder (OCD)." | 5.06 | Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination. ( Simeon, JG; Thatte, S; Wiggins, D, 1990) |
| "A group of 75 outpatients suffering from obsessive-compulsive disorder began treatment with the bicyclic antidepressant fluoxetine in an open clinical setting." | 5.06 | Long-term fluoxetine treatment of a large number of obsessive-compulsive patients. ( Hoffman, JS; Kenin, M; Knepple, ED; Levine, R, 1989) |
| "The selective serotonin reuptake blocker fluoxetine was administered to 49 patients with obsessive-compulsive disorder in a 12-week open clinical trial." | 5.06 | Fluoxetine treatment of obsessive-compulsive disorder: an open clinical trial. ( Campeas, R; Davies, S; Fairbanks, J; Hatterer, J; Hollander, E; Liebowitz, MR; Papp, L; Sandberg, D; Schneier, F; Stein, M, 1989) |
| "In a 9-week open label study, seven outpatients with obsessive-compulsive disorder were treated with fluoxetine, a selective inhibitor of neuronal reuptake of serotonin." | 5.06 | An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder. ( Chouinard, G; Fontaine, R, 1986) |
| "Convincing evidence from placebo-referenced randomized controlled trials supports efficacy for clomipramine and selective serotonin reuptake inhibitors for acute treatment of obsessive-compulsive disorder." | 4.84 | Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder. ( Fineberg, NA; Ipser, J; Pallanti, S; Pampaloni, I; Stein, DJ, 2007) |
| "This meta-analysis assessed aggression and/or hostility-related events in children and adolescents treated with fluoxetine (n = 376) compared with placebo (n = 255)." | 4.84 | Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placebo. ( Allen, AJ; Caldwell, C; Nilsson, M; Plewes, J; Tauscher-Wisniewski, S, 2007) |
| "The largest body of work supporting the use of medications for childhood anxiety came from studies of obsessive-compulsive disorder, where clomipramine and fluoxetine have been found effective in systematic studies." | 4.79 | Current knowledge of medications for the treatment of childhood anxiety disorders. ( Allen, AJ; Leonard, H; Swedo, SE, 1995) |
| "The most common effective treatments for obsessive-compulsive disorder include clomipramine, fluoxetine, and exposure-based behavior therapy." | 4.78 | Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: a meta-analysis. ( Cox, BJ; Lee, PS; Morrison, B; Swinson, RP, 1993) |
| "We report a case of an 18-year-old, middle-eastern female patient who developed onychotillomania when she was being treated with paroxetine for obsessive-compulsive disorder and was showing partial improvement." | 4.12 | Fluoxetine for the treatment of onychotillomania associated with obsessive-compulsive disorder: a case report. ( Aljhani, S, 2022) |
| "The principal aim of the current study was to check the potential contribution of repurposing of magic shotgun nature of curcumin (rhizomes of Curcuma longa) with scattergun approach- proceeding a pioneer 'fine-tune' for obsessive-compulsive disorder." | 4.02 | Magic Shotgun Nature with Scattergun Approach of Curcumin Repurposing in Obsessive-compulsive Disorder: A Novel Metaphysician of Drug Discovery. ( Gupta, A; Mishra, A; Mishra, RK, 2021) |
| "Fluoxetine's efficacy has been principally based on convincing open-label studies and clinical practice." | 3.77 | Serotonergic antidepressants and their efficacy in obsessive compulsive disorder. ( Dominguez, RA, 1992) |
| "The aim of this study was to investigate the efficacy and safety of fluoxetine in the treatment of obsessive-compulsive disorder (OCD) in preschool children." | 3.75 | Efficacy and safety of fluoxetine in preschool children with obsessive-compulsive disorder. ( Coskun, M; Zoroglu, S, 2009) |
| "A standardized research protocol that combines different methods of investigation (genetics, neuropsychology, morphometric magnetic resonance imaging and molecular neuroimaging of the dopamine transporter) obtained before and after treatment of drug-naïve adult obsessive-compulsive disorder patients submitted to a sequentially allocated 12-week clinical trial with a selective serotonin reuptake inhibitor (fluoxetine) and group cognitive-behavioral therapy." | 3.75 | The drug-naïve OCD patients imaging genetics, cognitive and treatment response study: methods and sample description. ( Batistuzzo, MC; Belotto-Silva, C; Borcato, S; Bressan, RA; Busatto, GF; Cappi, C; Cecconi, JP; D'Alcante, CC; Diniz, JB; Dougherty, DD; Duran, FL; Hoexter, MQ; Hounie, AG; Joaquim, MA; Lopes, AC; Marques, AH; Mathis, MA; Miguel, EC; Moraes, I; Muniz, RK; Rosa, AC; Sampaio, AS; Santos, LC; Shavitt, RG; Taub, A, 2009) |
| "We have proposed rewarded T-maze alternation as a model of obsessive-compulsive disorder (OCD): the serotonin agonist m-chlorophenylpiperazine (mCPP) increments persistence therein, while chronic pretreatment with selective serotonin reuptake inhibitor (SSRI fluoxetine) but not benzodiazepine or desipramine abolishes mCPP effects." | 3.74 | Dopaminergic and serotonergic modulation of persistent behaviour in the reinforced spatial alternation model of obsessive-compulsive disorder. ( Boulougouris, V; Kalogerakou, S; Kontis, D; Papadimitriou, GN; Papadopoulos, S; Papakosta, VM; Poulopoulou, C; Tsaltas, E, 2008) |
| "Consecutive outpatients with obsessive-compulsive disorder were evaluated for response to a two-month fluoxetine therapy course by Yale-Brown obsessive-compulsive scale according to the clinical subtype of the disease." | 3.74 | Effectiveness of fluoxetine on various subtypes of obsessive-compulsive disorder. ( Farhang, S; Farnam, A; Goreishizadeh, MA, 2008) |
| " Her mother had been taking fluoxetine (20 mg daily) during the second and third trimesters of her pregnancy." | 3.74 | Prolonged neonatal complications after in utero exposure to fluoxetine. ( Alehan, F; Gürakan, B; Saygi, S; Tarcan, A, 2008) |
| "(1) Four drugs are approved in France for patients with obsessive-compulsive disorders, namely clomipramine and three selective serotonin reuptake inhibitors (SSRIs): fluoxetine, paroxetine and sertraline." | 3.72 | Fluvoxamine: new indication. No progress in obsessive-compulsive disorder. ( , 2004) |
| "Two individuals from a large HD pedigree with a very high prevalence of obsessive-compulsive disorder (OCD) have been treated with fluoxetine, an SSRI." | 3.71 | Fluoxetine in the treatment of Huntington's disease. ( Daniele, F; De Marchi, N; Ragone, MA, 2001) |
| "Alterations in arginine vasopressin regulation and secretion have been proposed as one possible biochemical abnormality in patients with obsessive-compulsive disorder." | 3.71 | Vasopressin-dependent flank marking in golden hamsters is suppressed by drugs used in the treatment of obsessive-compulsive disorder. ( Ferris, CF; Koppel, G; Messenger, T; Rasmussen, MF, 2001) |
| "Twenty-one pediatric subjects with diagnoses of autistic disorder or other pervasive developmental disorders, 6-15 years old and stabilized with a consistent dose of fluvoxamine or fluoxetine, were recruited for the study; 16 successfully completed the imaging protocol." | 3.71 | Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders. ( Cowan, C; Dager, SR; Dawson, G; Strauss, WL; Unis, AS, 2002) |
| "We present a 15-year-old girl with depression, an obsessive compulsive disorder and conduct disorder, who developed EPS (torticollis, bradykinesia and cogwheel rigidity) while on fluoxetine." | 3.71 | Fluoxetine-induced extrapyramidal symptoms in an adolescent: a case report. ( Avci, A; Diler, RS; Yolga, AY, 2002) |
| " We therefore describe an adolescent sex offender who met DSM-IV criteria for multiple paraphilias (except for the age criterion), bipolar type II disorder, and OCD, whose paraphilic urges and behaviors, depression, and violent obsessions responded to open label fluoxetine after failing to respond to long-term residential treatment." | 3.70 | An adolescent male with multiple paraphilias successfully treated with fluoxetine. ( Galli, VB; McConville, BJ; McElroy, SL; Raute, NJ, 1998) |
| "Clomipramine appeared much more effective and better tolerated than fluoxetine in this very old patient despite its potential anticholinergic effect and the coexistence of Alzheimer disease." | 3.70 | Treatment of obsessive-compulsive disorder using clomipramine in a very old patient. ( Trappler, B, 1999) |
| "Prospectively identified fluoxetine-exposed pregnancies were evaluated to determine whether fluoxetine, a serotonin reuptake inhibitor commonly used for the treatment of depression and obsessive-compulsive disorder, might be associated with neonatal complications after maternal fluoxetine exposure during the third trimester through delivery." | 3.69 | Effects of third trimester fluoxetine exposure on the newborn. ( Goldstein, DJ, 1995) |
| " To investigate this phenomenon as a possible animal model of obsessive-compulsive disorder (OCD), rats were treated for 5 weeks with fluoxetine, an antidepressant that relieves OCD symptoms in humans (5 mg/kg, 2." | 3.69 | Effects of serotonergic agents on food-restriction-induced hyperactivity. ( Altemus, M; Galliven, E; Glowa, JR; Leong, YM; Murphy, DL, 1996) |
| "Three patients with histories of impotence experienced a return of sexual potency after treatment with fluoxetine." | 3.68 | Association of fluoxetine and return of sexual potency in three elderly men. ( Levitte, SS; Smith, DM, 1993) |
| " Psychiatrists were much more likely than family practitioners to prescribe fluoxetine for obsessive-compulsive disorder (OCD), and more likely to prescribe for a patient with a history of substance abuse or seizure disorder." | 3.68 | Prescribing attitudes of different physician groups regarding fluoxetine. ( DeVane, CL; Levin, GM, 1993) |
| " We report a case of a possible interaction with pimozide which led to a potentially life threatening bradycardia." | 3.68 | Possible interaction between fluoxetine and pimozide causing sinus bradycardia. ( Ahmed, I; Dagincourt, PG; Miller, LG; Shader, RI, 1993) |
| "In vivo 19fluorine nuclear magnetic resonance spectroscopy was used to measure the brain concentration of fluoxetine and norfluoxetine in five patients with obsessive-compulsive disorder and three with major depression." | 3.68 | Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. ( Clancy, K; Fava, M; Flood, JG; Gonzalez, RG; Guimaraes, AR; Pearlman, JD; Puopolo, PR; Renshaw, PF; Rosenbaum, JF, 1992) |
| "Four patients treated with fluoxetine alone developed generalized urticaria." | 3.68 | Adverse cutaneous reactions associated with fluoxetine strategy for reintroduction of this drug in selected patients. ( Binkley, KE; Joffee, RT; Levitt, A; Leznoff, A; Richter, MA, 1992) |
| "We used positron emission tomography to investigate local cerebral metabolic rates for glucose (LCMRG1c) in patients with obsessive-compulsive disorder before and after treatment with either fluoxetine hydrochloride or behavior therapy." | 3.68 | Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. ( Alazraki, A; Baxter, LR; Bergman, KS; Ferng, HK; Guze, BH; Mazziotta, JC; Munford, P; Schwartz, JM; Selin, CE; Szuba, MP, 1992) |
| "To investigate the effects of drug treatment in childhood-onset obsessive-compulsive disorder (OCD), we repeated positron emission tomographic scans in 13 adults with OCD (eight taking clomipramine, two taking fluoxetine, and three taking no drug) after at least 1 year of pharmacotherapy." | 3.68 | Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy. ( Goldberger, EL; Grady, CL; Leonard, HL; Pietrini, P; Rapoport, JL; Rapoport, SI; Rettew, DC; Schapiro, MB; Swedo, SE, 1992) |
| "An open trial of pharmacological treatment with fluoxetine, ranging from 20 mg every other day to 80 mg per day, led to a significant improvement in Clinical Global Impressions ratings of Clinical Severity in 15 of 23 subjects with autistic disorder and 10 of 16 subjects with mental retardation." | 3.68 | Fluoxetine treatment of children and adults with autistic disorder and mental retardation. ( Cook, EH; Jaselskis, C; Leventhal, BL; Rowlett, R, 1992) |
| "Two patients suffering from severe obsessive-compulsive disorder which had proven refractory to clomipramine and/or phenelzine treatment were successfully treated with fluoxetine, a new drug with a strong serotonin uptake inhibiting action." | 3.68 | Fluoxetine treatment of obsessive-compulsive disorder. ( Ledwidge, B; Solyom, C; Solyom, L, 1991) |
| "Self-injurious ideation or behavior appeared de novo or intensified during fluoxetine treatment of obsessive-compulsive disorder in six patients, age 10 to 17 years old, who were among 42 young patients receiving fluoxetine for obsessive-compulsive disorder at a university clinical research center." | 3.68 | Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. ( Anderson, GM; Chappell, PB; Hardin, MT; King, RA; Lombroso, P; Riddle, MA; Scahill, L, 1991) |
| "Ten outpatients meeting DSM-III-R criteria for obsessive-compulsive disorder completed a 32-week, open-label study with fluoxetine, a selective serotonin reuptake blocker." | 3.68 | Efficacy of long-term fluoxetine treatment of obsessive-compulsive disorder. ( Frenkel, A; Nezu, A; Rosenthal, J; Winston, A, 1990) |
| "A 12-week open trial of fluoxetine in 61 obsessive-compulsive disorder patients significantly improved depressive and obsessive-compulsive symptoms." | 3.67 | Open trial of fluoxetine in obsessive-compulsive disorder. ( Baer, L; Buttolph, L; Holland, A; Jenike, MA; Ricciardi, J, 1989) |
| " Adverse events were also assessed." | 2.94 | The safety and efficacy of transcranial direct current stimulation as add-on therapy to fluoxetine in obsessive-compulsive disorder: a randomized, double-blind, sham-controlled, clinical trial. ( Amanat, M; Behzadmanesh, J; Mousavi, SV; Safary, V; Salehi, B; Salehi, M; Yoonesi, A; Yoosefee, S, 2020) |
| "Fluoxetine (FLX) has been one of the most widely studied selective serotonin reuptake inhibitors in adolescents." | 2.79 | Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder. ( Arnaiz, JA; Blázquez, A; Gassó, P; Lafuente, A; Lázaro, L; Mas, S; Méndez, I; Plana, MT; Torra, M, 2014) |
| "Relapse of major depressive disorder (MDD) is a common clinical problem." | 2.75 | Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. ( Baer, L; Chen, Y; Chuzi, S; Clain, A; Fava, M; Johnson, D; McGrath, PJ; Papakostas, GI; Sinicropi-Yao, L; Stewart, JW; Yang, H, 2010) |
| "" These behaviors emerged despite gradual dose elevation (2-5 mg/wk), conservative dosing (maximum 40 mg daily), and careful weekly outpatient monitoring of each patient." | 2.69 | Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder. ( Birmaher, B; Go, FS; Malley, EE; Rosenberg, DR, 1998) |
| "Metergoline levels were higher in fluoxetine-treated patients." | 2.69 | Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients. ( Altemus, M; Benjamin, J; Greenberg, BD; Huang, SJ; Keuler, D; Martin, JD; Murphy, DL, 1998) |
| " The dosage of FLX was fixed at either 20, 40, or 60 mg per day." | 2.69 | Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder. ( Dossenbach, M; Hornik, K; Meszaros, K; Twaroch, T; Zapotoczky, HG; Zitterl, W; Zitterl-Eglseer, K, 1999) |
| "Fluoxetine was significantly superior to placebo in the treatment of skin picking according to two of the three measures for the completer analysis and to one of the three measures for the intent-to-treat analysis." | 2.68 | A double-blind trial of fluoxetine in pathologic skin picking. ( Gross, S; Hollander, E; Islam, N; Schmeidler, J; Simeon, D; Stein, DJ, 1997) |
| "Fluoxetine was well tolerated during both 24-week continuation periods." | 2.67 | Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. ( Birkett, M; Genduso, L; Koran, L; Tollefson, GD, 1994) |
| "Canine acral lick dermatitis is a naturally occurring disorder in which excessive licking of paws or flank can produce ulcers and infection that require medical treatment." | 2.67 | Drug treatment of canine acral lick. An animal model of obsessive-compulsive disorder. ( Kriete, M; Rapoport, JL; Ryland, DH, 1992) |
| "In general, effective treatments for trichotillomania have been elusive." | 2.67 | Clinical characteristics of trichotillomania and its response to fluoxetine. ( Jones, JS; Molcho, A; Stanley, B; Stanley, M; Winchel, RM, 1992) |
| "improves the core features of autism (social interaction, communication and behavioural problems);2." | 2.49 | Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). ( Brignell, A; Hazell, P; Randall, M; Silove, N; Williams, K, 2013) |
| "improves the core features of autism (social interaction, communication and behavioural problems); 2." | 2.46 | Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). ( Hazell, P; Silove, N; Wheeler, DM; Williams, K, 2010) |
| "The frequent comorbidity of OCD and Sydenham's chorea and similar postulates of basal ganglia dysfunction for both disorders suggest that Sydenham's chorea may serve as a medical model for OCD." | 2.39 | Childhood movement disorders and obsessive compulsive disorder. ( Leonard, HL; Swedo, SE, 1994) |
| "Sertraline was found to be modestly efficacious and associated with numerous side effects and discontinuation rates in patients who had previously discontinued fluoxetine." | 2.39 | Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? ( Cole, JO; Kando, JC; Tohen, M; Weiss, MK; Zarate, CA, 1996) |
| "Treatment with fluoxetine 60 mg/day for 12 weeks reduced obsessive symptoms by 60%, improving her quality of life." | 1.48 | The Stuck Song Syndrome: A Case of Musical Obsessions. ( Lizarazo Rodríguez, IL; Orjuela Rojas, JM, 2018) |
| "The mice with experimental autoimmune encephalomyelitis exhibited exaggerated grooming activity." | 1.48 | Auto-Reactive Th17-Cells Trigger Obsessive-Compulsive-Disorder Like Behavior in Mice With Experimental Autoimmune Encephalomyelitis. ( Kant, R; Pasi, S; Surolia, A, 2018) |
| " An understanding of CYP450 metabolism and drug interaction as well as metabolism phenotypes should inform prescribing and dosing psychotropic medications." | 1.46 | Case report: Cytochrome P450 implications for comorbid ADHD and OCD pharmacotherapy. ( Hogan, MK; Rao, NP, 2017) |
| "Management and resolution of the hydrocephalus was temporally associated with an improvement in his OCD compulsion symptoms." | 1.43 | Pediatric Obsessive-Compulsive Disorder Exacerbation and Obstructive Hydrocephalus: A Case Report. ( Bleakley, C; Leung, A; Loh, A; Saran, K; Stewart, SE, 2016) |
| "Fluoxetine 5 mg/day was started and gradually increased to 20 mg/day." | 1.43 | Diagnosis and treatment of obsessive compulsive behavior in a boy with Duchenne muscular dystrophy and autism spectrum disorder: A case report. ( Collin, P; Hendriksen, JG; Klinkenberg, S; Niks, EH; Vles, JS; Wong, B, 2016) |
| " Fluoxetine (FLX), an SSRI on chronic administration (10mg/kg, 21 days) restored the increase in SAB induced by 8-OHDPAT in mice which is in line with the findings earlier reported for rats." | 1.39 | Oxcarbazepine and fluoxetine protect against mouse models of obsessive compulsive disorder through modulation of cortical serotonin and CREB pathway. ( Arora, T; Bhowmik, M; Khanam, R; Vohora, D, 2013) |
| "Kleptomania is an impulse control disorder characterized by a recurrent failure to resist the impulse to steal worthless objects that are not needed for personal use." | 1.38 | Naltrexone treatment of kleptomania: a case report. ( Belkız Güngör, B; Çetinay Aydın, P; Gülseren, L, 2012) |
| "desipramine) treatment (both 10 mg/kg; 20 mg/kg x 21 days)." | 1.35 | Stereotypic behaviour in the deer mouse: pharmacological validation and relevance for obsessive compulsive disorder. ( Harvey, BH; Korff, S; Stein, DJ, 2008) |
| "Developmental stuttering and tics share many clinical and therapeutical aspects." | 1.34 | Severe stuttering and motor tics responsive to cocaine. ( Linazasoro, G; Van Blercom, N, 2007) |
| "fluoxetine) anxiolytics inhibit marble burying." | 1.33 | A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants. ( Kolb, Y; Nicolas, LB; Prinssen, EP, 2006) |
| "Treatment with fluoxetine for 6 months resulted in significant symptom relief and an increasing density of serotonin transporter sites when compared to the beginning of treatment." | 1.32 | Fluoxetine in Alzheimer's disease with severe obsessive compulsive symptoms and a low density of serotonin transporter sites. ( Bodner, T; Donnemiller, E; Gurka, P; Marksteiner, J; Walch, T, 2003) |
| "When clomipramine was changed to fluoxetine, the OCD symptoms were responsive even at a starting dosage of 20 mg/day." | 1.31 | Clomipramine-resistant, fluoxetine-responsive obsessive compulsive disorder: a case report. ( Paholpak, S, 2002) |
| "Serotonin syndrome is the result of the drug interaction that enhances serotonergic tone in the central nervous system." | 1.30 | Serotonin syndrome presenting with migrainelike stroke. ( Molaie, M, 1997) |
| "Fluoxetine treatment yielded an enhanced [3H]5-HT release in the three brain areas, but a desensitization of the 5-HT autoreceptor only in the hypothalamus and orbitofrontal cortex." | 1.30 | Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive-compulsive disorder. ( Bergqvist, PB; Blier, P; Bouchard, C, 1999) |
| " Subsequent chronic administration of the serotonin reuptake inhibitor fluoxetine reduces schedule-induced polydipsia over 2-4 weeks." | 1.29 | Changes in paroxetine binding in the cerebral cortex of polydipsic rats. ( Corbett, R; Kongsamut, S; Roehr, J; Woods, A, 1995) |
| " Chronic administration of the selective serotonin re-uptake inhibitors fluoxetine and clomipramine (CMI) at 5 mg/kg per day and fluvoxamine at 10 mg/kg twice a day significantly decreased schedule-induced polydipsia (SIP) on day 15 and throughout the remainder of the study compared to control rats." | 1.29 | Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder. ( Corbett, R; Cornfeldt, M; Dunn, RW; Smith, C; Szewczak, M; Woods, A, 1993) |
| "Symptoms were divided into paraphilias, nonparaphilic sexual addictions, and sexual obsessions." | 1.28 | Serotonergic medications for sexual obsessions, sexual addictions, and paraphilias. ( Anthony, DT; Fallon, BA; Hollander, E; Klein, DF; Liebowitz, MR; Schneier, FR; Stein, DJ, 1992) |
| "Hypochondriasis is a disorder for which there are no established effective treatments." | 1.28 | Hypochondriasis and obsessive compulsive disorder: overlaps in diagnosis and treatment. ( Fallon, BA; Hollander, E; Javitch, JA; Liebowitz, MR, 1991) |
| "Fenfluramine is a serotonin releaser and reuptake blocker which is marketed as an anorectic agent." | 1.28 | Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. ( DeCaria, CM; Hollander, E; Klein, DF; Liebowitz, MR; Schneier, FR; Schneier, HA, 1990) |
| " In general, fluoxetine, which was administered from 4 to 20 weeks at a dosage of 10 or 40 mg per day, was well tolerated." | 1.28 | Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: preliminary clinical experience. ( Hardin, MT; King, R; Riddle, MA; Scahill, L; Woolston, JL, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (5.75) | 18.7374 |
| 1990's | 214 (53.50) | 18.2507 |
| 2000's | 77 (19.25) | 29.6817 |
| 2010's | 75 (18.75) | 24.3611 |
| 2020's | 11 (2.75) | 2.80 |
| Authors | Studies |
|---|---|
| Bös, M | 1 |
| Jenck, F | 1 |
| Martin, JR | 1 |
| Moreau, JL | 1 |
| Sleight, AJ | 1 |
| Wichmann, J | 1 |
| Widmer, U | 1 |
| Bez, Y | 1 |
| Coffey, BJ | 2 |
| Manning, EE | 1 |
| Geramita, MA | 1 |
| Piantadosi, SC | 1 |
| Pierson, JL | 1 |
| Ahmari, SE | 2 |
| Aljhani, S | 3 |
| Thompson, SL | 2 |
| Welch, AC | 1 |
| Ho, EV | 3 |
| Bessa, JM | 1 |
| Portugal-Nunes, C | 1 |
| Morais, M | 1 |
| Young, JW | 1 |
| Knowles, JA | 2 |
| Dulawa, SC | 3 |
| Reddihough, DS | 1 |
| Marraffa, C | 1 |
| Mouti, A | 1 |
| O'Sullivan, M | 1 |
| Lee, KJ | 1 |
| Orsini, F | 1 |
| Hazell, P | 3 |
| Granich, J | 1 |
| Whitehouse, AJO | 1 |
| Wray, J | 1 |
| Dossetor, D | 1 |
| Santosh, P | 1 |
| Silove, N | 3 |
| Kohn, M | 1 |
| Ne'eman, A | 1 |
| Albrecht, K | 1 |
| Kapp, SK | 1 |
| Sanikhani, NS | 1 |
| Modarressi, MH | 1 |
| Jafari, P | 1 |
| Vousooghi, N | 1 |
| Shafei, S | 1 |
| Akbariqomi, M | 1 |
| Heidari, R | 1 |
| Lavasani, PS | 1 |
| Yazarlou, F | 1 |
| Motevaseli, E | 1 |
| Ghafouri-Fard, S | 1 |
| Maneeton, N | 1 |
| Maneeton, B | 1 |
| Karawekpanyawong, N | 1 |
| Woottiluk, P | 1 |
| Putthisri, S | 1 |
| Srisurapanon, M | 1 |
| Tatay-Manteiga, A | 1 |
| Yoosefee, S | 1 |
| Amanat, M | 1 |
| Salehi, M | 1 |
| Mousavi, SV | 1 |
| Behzadmanesh, J | 1 |
| Safary, V | 1 |
| Yoonesi, A | 1 |
| Salehi, B | 1 |
| Kazemi, F | 1 |
| Vosough, I | 1 |
| Sepahi, S | 1 |
| Mohajeri, SA | 1 |
| Manjappa, P | 1 |
| Balachander, S | 1 |
| Naaz, S | 1 |
| Nadella, RK | 1 |
| Shukla, T | 1 |
| Paul, P | 1 |
| Purushottam, M | 1 |
| Janardhan Reddy, YC | 2 |
| Jain, S | 2 |
| Viswanath, B | 1 |
| Sud, R | 1 |
| Mishra, RK | 1 |
| Mishra, A | 1 |
| Gupta, A | 1 |
| Costa, DLDC | 1 |
| Barbosa, VS | 1 |
| Requena, G | 2 |
| Shavitt, RG | 12 |
| Pereira, CAB | 1 |
| Diniz, JB | 10 |
| Uvais, NA | 1 |
| Sreeraj, VS | 1 |
| Mitra, S | 1 |
| Mucha, M | 1 |
| Owen, S | 1 |
| Bult-Ito, A | 1 |
| Krooks, JA | 1 |
| Weatherall, AG | 1 |
| Holland, PJ | 1 |
| Faye, A | 1 |
| Kirpekar, V | 1 |
| Tadke, R | 1 |
| Gawande, S | 1 |
| Bhave, S | 1 |
| Hogan, MK | 1 |
| Rao, NP | 2 |
| Gupta, T | 1 |
| Nebhinani, N | 1 |
| Singhai, K | 1 |
| Suthar, N | 1 |
| Phadnis, P | 1 |
| Dey Sarkar, P | 1 |
| Rajput, MS | 1 |
| Lu, ZA | 1 |
| Mu, W | 1 |
| Osborne, LM | 1 |
| Cordner, ZA | 1 |
| Fatori, D | 1 |
| de Bragança Pereira, CA | 1 |
| Asbahr, FR | 2 |
| Alvarenga, PG | 1 |
| de Mathis, MA | 1 |
| Rohde, LA | 1 |
| Leckman, JF | 5 |
| March, JS | 2 |
| Polanczyk, GV | 1 |
| Miguel, EC | 9 |
| Farnia, V | 1 |
| Gharehbaghi, H | 1 |
| Alikhani, M | 1 |
| Almasi, A | 1 |
| Golshani, S | 1 |
| Tatari, F | 1 |
| Davarinejad, O | 1 |
| Salemi, S | 1 |
| Sadeghi Bahmani, D | 1 |
| Holsboer-Trachsler, E | 1 |
| Brand, S | 1 |
| Orjuela Rojas, JM | 1 |
| Lizarazo Rodríguez, IL | 1 |
| Kant, R | 1 |
| Pasi, S | 1 |
| Surolia, A | 1 |
| Garabadu, D | 1 |
| Kumar, V | 1 |
| Tural, Ü | 2 |
| Çorapçıoğlu, A | 1 |
| Boşgelmez, Ş | 1 |
| Köroğlu, G | 1 |
| Ünver, H | 1 |
| Duman, C | 1 |
| Önder, E | 2 |
| Arora, T | 1 |
| Bhowmik, M | 1 |
| Khanam, R | 1 |
| Vohora, D | 1 |
| Spellman, T | 1 |
| Douglass, NL | 1 |
| Kheirbek, MA | 1 |
| Simpson, HB | 3 |
| Deisseroth, K | 1 |
| Gordon, JA | 1 |
| Hen, R | 1 |
| da Conceição Costa, DL | 1 |
| Castro Cesar, RC | 1 |
| Joaquim, MA | 2 |
| Borcato, S | 3 |
| Valério, C | 3 |
| Williams, K | 2 |
| Brignell, A | 1 |
| Randall, M | 1 |
| Kantak, PA | 1 |
| Bobrow, DN | 1 |
| Nyby, JG | 1 |
| Costa, DL | 1 |
| Cassab, RC | 1 |
| Pereira, CA | 2 |
| Blázquez, A | 2 |
| Mas, S | 2 |
| Plana, MT | 1 |
| Gassó, P | 2 |
| Méndez, I | 1 |
| Torra, M | 1 |
| Arnaiz, JA | 2 |
| Lafuente, A | 2 |
| Lázaro, L | 2 |
| Dembo, JS | 1 |
| Denenberg, S | 1 |
| Rao, SA | 1 |
| Rao, MG | 1 |
| Varambally, S | 1 |
| Gangadhar, BN | 1 |
| Zhang, K | 1 |
| Cao, L | 1 |
| Zhu, W | 1 |
| Wang, G | 1 |
| Wang, Q | 1 |
| Hu, H | 1 |
| Zhao, M | 1 |
| Gorenstein, G | 1 |
| Gorenstein, C | 2 |
| de Oliveira, MC | 1 |
| Pekrul, SR | 1 |
| Fitzgerald, KD | 1 |
| Katzka, WR | 1 |
| Sharifi, MF | 1 |
| Karadag, M | 1 |
| Gokcen, C | 1 |
| Bayar, H | 1 |
| Aksoy, I | 1 |
| Kar, SK | 1 |
| Garg, K | 1 |
| Youssef, NA | 1 |
| Ara, A | 1 |
| Bhat, I | 1 |
| Giasuddin, NA | 2 |
| Nahar, JS | 2 |
| Morshed, NM | 2 |
| Balhara, YP | 2 |
| Cawkwell, P | 1 |
| Lawler, A | 1 |
| Maneta, E | 1 |
| Figueiredo, T | 1 |
| Segenreich, D | 1 |
| Mattos, P | 1 |
| Usuki, T | 1 |
| Takato, T | 1 |
| Lu, Q | 1 |
| Sakai, H | 1 |
| Bando, K | 1 |
| Kiyonari, H | 1 |
| Sakane, F | 1 |
| Jha, S | 1 |
| Kumar, P | 1 |
| Kumar, R | 1 |
| Das, A | 1 |
| Leung, A | 1 |
| Bleakley, C | 1 |
| Loh, A | 1 |
| Saran, K | 1 |
| Stewart, SE | 1 |
| Hendriksen, JG | 1 |
| Klinkenberg, S | 1 |
| Collin, P | 1 |
| Wong, B | 1 |
| Niks, EH | 1 |
| Vles, JS | 1 |
| Dantas, LM | 1 |
| Rodríguez, N | 1 |
| Boloc, D | 1 |
| Ullrich, M | 1 |
| Weber, M | 1 |
| Post, AM | 1 |
| Popp, S | 1 |
| Grein, J | 1 |
| Zechner, M | 1 |
| Guerrero González, H | 1 |
| Kreis, A | 1 |
| Schmitt, AG | 1 |
| Üçeyler, N | 1 |
| Lesch, KP | 2 |
| Schuh, K | 1 |
| Yanover, T | 1 |
| Thompson, JK | 1 |
| Straub, DM | 1 |
| Kontis, D | 2 |
| Boulougouris, V | 1 |
| Papakosta, VM | 1 |
| Kalogerakou, S | 1 |
| Papadopoulos, S | 1 |
| Poulopoulou, C | 1 |
| Papadimitriou, GN | 1 |
| Tsaltas, E | 2 |
| Fontenelle, LF | 3 |
| Leite, MA | 1 |
| Farnam, A | 1 |
| Goreishizadeh, MA | 1 |
| Farhang, S | 1 |
| Hergüner, S | 1 |
| Ozyildirim, I | 1 |
| Tanidir, C | 1 |
| Alehan, F | 1 |
| Saygi, S | 1 |
| Tarcan, A | 1 |
| Gürakan, B | 1 |
| Purper-Ouakil, D | 1 |
| Vitiello, B | 2 |
| Alaghband-Rad, J | 1 |
| Hakimshooshtary, M | 1 |
| Coskun, M | 1 |
| Zoroglu, S | 1 |
| S N, U | 1 |
| J M, V | 1 |
| N S, J | 1 |
| P V, D | 1 |
| Yang, H | 1 |
| Chuzi, S | 1 |
| Sinicropi-Yao, L | 1 |
| Johnson, D | 1 |
| Chen, Y | 1 |
| Clain, A | 1 |
| Baer, L | 8 |
| McGrath, PJ | 1 |
| Stewart, JW | 1 |
| Fava, M | 2 |
| Papakostas, GI | 1 |
| Landeros-Weisenberger, A | 1 |
| Bloch, MH | 1 |
| Kelmendi, B | 1 |
| Wegner, R | 1 |
| Nudel, J | 1 |
| Dombrowski, P | 1 |
| Pittenger, C | 1 |
| Krystal, JH | 1 |
| Goodman, WK | 7 |
| Coric, V | 1 |
| Wald, R | 1 |
| Dodman, N | 1 |
| Shuster, L | 1 |
| Chon, MW | 1 |
| Choi, JS | 1 |
| Kang, DH | 1 |
| Jung, MH | 1 |
| Kwon, JS | 1 |
| Sayyah, M | 4 |
| Boostani, H | 2 |
| Pakseresht, S | 2 |
| Malayeri, A | 4 |
| Hoexter, MQ | 4 |
| D'Alcante, CC | 4 |
| Cecconi, JP | 1 |
| Belotto-Silva, C | 3 |
| Hounie, AG | 1 |
| Moraes, I | 1 |
| Cappi, C | 1 |
| Sampaio, AS | 1 |
| Mathis, MA | 1 |
| Batistuzzo, MC | 4 |
| Lopes, AC | 4 |
| Rosa, AC | 1 |
| Muniz, RK | 1 |
| Marques, AH | 1 |
| Santos, LC | 1 |
| Taub, A | 1 |
| Duran, FL | 2 |
| Dougherty, DD | 3 |
| Busatto, GF | 3 |
| Bressan, RA | 3 |
| Maalouf, FT | 1 |
| Gilbert, AR | 1 |
| Harrington, M | 1 |
| Wheeler, DM | 1 |
| Soltani, F | 1 |
| Feizy, F | 1 |
| Siahpoosh, A | 1 |
| Motlagh, I | 1 |
| Ceylan, MF | 1 |
| Akca, ÖF | 1 |
| Besiroglu, L | 1 |
| Sozen, M | 1 |
| Ozbebit, O | 1 |
| Avcu, S | 1 |
| Selvi, Y | 1 |
| Bora, A | 1 |
| Atli, A | 1 |
| Unal, O | 1 |
| Bulut, MD | 1 |
| Anand, N | 1 |
| Sudhir, PM | 1 |
| Math, SB | 1 |
| Thennarasu, K | 1 |
| Korkmaz, S | 1 |
| Işik, U | 1 |
| Korkmaz, H | 1 |
| Malavazzi, DM | 1 |
| Fossaluza, V | 4 |
| Seixas, AA | 1 |
| Morelli, D | 1 |
| Koran, L | 2 |
| de Souza Duran, FL | 1 |
| Deckersbach, T | 2 |
| Rickards, H | 1 |
| Cavanna, AE | 1 |
| Worrall, R | 1 |
| Ercan, ES | 1 |
| Kandulu, R | 1 |
| Akyol Ardic, U | 1 |
| Okada, T | 1 |
| Egashira, N | 1 |
| Okuno, R | 1 |
| Shirakawa, A | 1 |
| Nagao, M | 1 |
| Mishima, K | 1 |
| Iwasaki, K | 1 |
| Oishi, R | 1 |
| Fujiwara, M | 1 |
| Olapour, A | 1 |
| Saeedabad, Ys | 1 |
| Yazdan Parast, R | 1 |
| Malloy-Diniz, L | 1 |
| Evans, KC | 1 |
| Dixit, PV | 1 |
| Parihar, G | 1 |
| Jain, DK | 1 |
| Jaiswal, P | 1 |
| Jakubovski, E | 1 |
| Miguel, E | 1 |
| Sahu, JK | 1 |
| Singhi, P | 1 |
| Malhotra, S | 1 |
| Andrade, C | 2 |
| Çetinay Aydın, P | 1 |
| Belkız Güngör, B | 1 |
| Gülseren, L | 1 |
| Sobhan, MA | 1 |
| Woehrle, NS | 1 |
| Klenotich, SJ | 1 |
| Jamnia, N | 1 |
| Olvera-Hernández, S | 1 |
| Chavira, R | 1 |
| Fernández-Guasti, A | 2 |
| Kampman, M | 1 |
| Keijsers, GP | 1 |
| Hoogduin, CA | 1 |
| Verbraak, MJ | 1 |
| Takeuchi, H | 1 |
| Yatsugi, S | 1 |
| Yamaguchi, T | 1 |
| Liebowitz, MR | 15 |
| Turner, SM | 3 |
| Piacentini, J | 2 |
| Beidel, DC | 3 |
| Clarvit, SR | 1 |
| Davies, SO | 1 |
| Graae, F | 2 |
| Jaffer, M | 2 |
| Lin, SH | 1 |
| Sallee, FR | 2 |
| Schmidt, AB | 1 |
| Paholpak, S | 1 |
| Stengler-Wenzke, K | 2 |
| Müller, U | 2 |
| Matthes-von-Cramon, G | 1 |
| Safranko, I | 1 |
| Joyce, PR | 1 |
| Rogers, GR | 1 |
| Miller, AL | 1 |
| Mulder, RT | 2 |
| Luty, SE | 1 |
| Kennedy, MA | 1 |
| Nielen, MM | 1 |
| Den Boer, JA | 2 |
| Marksteiner, J | 1 |
| Walch, T | 1 |
| Bodner, T | 1 |
| Gurka, P | 1 |
| Donnemiller, E | 1 |
| Kordon, A | 2 |
| Broocks, A | 1 |
| Hohagen, F | 2 |
| Levy, E | 1 |
| Margolese, HC | 1 |
| Sultan, S | 2 |
| Chouinard, G | 5 |
| Seymour, PM | 1 |
| Mendlowicz, MV | 2 |
| Versiani, M | 2 |
| Shapira, NA | 3 |
| Ward, HE | 2 |
| Mandoki, M | 1 |
| Murphy, TK | 2 |
| Yang, MC | 1 |
| Blier, P | 3 |
| Gothelf, D | 1 |
| Presburger, G | 1 |
| Zohar, AH | 1 |
| Burg, M | 1 |
| Nahmani, A | 1 |
| Frydman, M | 1 |
| Shohat, M | 1 |
| Inbar, D | 1 |
| Aviram-Goldring, A | 1 |
| Yeshaya, J | 1 |
| Steinberg, T | 1 |
| Finkelstein, Y | 1 |
| Frisch, A | 1 |
| Weizman, A | 1 |
| Apter, A | 1 |
| Swedo, S | 1 |
| Sayeed Khan, MN | 1 |
| Arshad, N | 1 |
| Ullah, N | 1 |
| Maina, G | 4 |
| Albert, U | 1 |
| Salvi, V | 1 |
| Bogetto, F | 4 |
| Sallinen, BJ | 1 |
| Nangle, DW | 1 |
| O'Grady, AC | 1 |
| Croarkin, P | 1 |
| Nam, T | 1 |
| Waldrep, D | 1 |
| Chrysikakou, S | 1 |
| Giannou, H | 1 |
| Biba, A | 1 |
| Pallidi, S | 1 |
| Christodoulou, A | 1 |
| Maillis, A | 1 |
| Rabavilas, A | 1 |
| Li, X | 1 |
| Morrow, D | 1 |
| Witkin, JM | 1 |
| Anderson, SW | 1 |
| Booker, MB | 1 |
| Labad, J | 1 |
| Menchón, JM | 2 |
| Alonso, P | 2 |
| Segalàs, C | 1 |
| Jiménez, S | 1 |
| Vallejo, J | 2 |
| Linazasoro, G | 1 |
| Van Blercom, N | 1 |
| Agrati, D | 1 |
| Reyes, R | 1 |
| Ferreira, A | 1 |
| Storch, EA | 1 |
| Larson, MJ | 1 |
| Geffken, GR | 1 |
| Valerio, H | 1 |
| Nicolas, LB | 1 |
| Kolb, Y | 1 |
| Prinssen, EP | 1 |
| Bailly, D | 1 |
| Zurowski, B | 1 |
| Wahl, K | 1 |
| Kotcher, L | 1 |
| Wieland, N | 2 |
| Coffey, B | 2 |
| Uday, G | 1 |
| Pravinkumar, B | 1 |
| Manish, W | 1 |
| Sudhir, U | 1 |
| Korff, S | 1 |
| Stein, DJ | 8 |
| Harvey, BH | 1 |
| Fineberg, NA | 1 |
| Pampaloni, I | 1 |
| Pallanti, S | 1 |
| Ipser, J | 1 |
| Timimi, S | 1 |
| Tundo, A | 1 |
| Salvati, L | 1 |
| Busto, G | 1 |
| Di Spigno, D | 1 |
| Falcini, R | 1 |
| Tauscher-Wisniewski, S | 1 |
| Nilsson, M | 1 |
| Caldwell, C | 1 |
| Plewes, J | 1 |
| Allen, AJ | 2 |
| Ghanizadeh, A | 1 |
| Anholt, GE | 1 |
| Kempe, P | 1 |
| de Haan, E | 1 |
| van Oppen, P | 1 |
| Cath, DC | 1 |
| Smit, JH | 1 |
| van Balkom, AJ | 1 |
| Gökbakan, M | 1 |
| Giakas, WJ | 1 |
| Campbell, M | 1 |
| Cueva, JE | 1 |
| Hartmann, L | 1 |
| Volk, S | 1 |
| Ravizza, L | 3 |
| Barzega, G | 3 |
| Bellino, S | 3 |
| Roehr, J | 1 |
| Woods, A | 2 |
| Corbett, R | 2 |
| Kongsamut, S | 1 |
| Leonard, H | 1 |
| Swedo, SE | 4 |
| Sternbach, H | 1 |
| Greist, JH | 3 |
| Jefferson, JW | 1 |
| Kobak, KA | 1 |
| Katzelnick, DJ | 1 |
| Serlin, RC | 1 |
| Friedman, EH | 3 |
| Geller, DA | 2 |
| Biederman, J | 1 |
| Reed, ED | 1 |
| Spencer, T | 1 |
| Wilens, TE | 1 |
| Smith, C | 1 |
| Szewczak, M | 1 |
| Dunn, RW | 1 |
| Cornfeldt, M | 1 |
| Smulevich, AB | 1 |
| Andriushchenko, AV | 1 |
| Morkovkina, IV | 1 |
| Tkhostov, ASh | 1 |
| Koliutskaia, EV | 1 |
| Leonard, HL | 3 |
| Eales, MJ | 1 |
| Layeni, AO | 1 |
| Munford, PR | 1 |
| Hand, I | 1 |
| Liberman, RP | 1 |
| Tollefson, GD | 4 |
| Birkett, M | 3 |
| Genduso, L | 1 |
| Dominguez, RA | 5 |
| Mestre, SM | 1 |
| Ricciardi, J | 3 |
| Keuthen, N | 1 |
| Pettit, AR | 1 |
| Buttolph, ML | 2 |
| Otto, M | 1 |
| Minichiello, W | 1 |
| Jenike, MA | 9 |
| Balon, R | 1 |
| Deltito, JA | 1 |
| Sewell, DD | 1 |
| Lopez, WM | 1 |
| Paulsen, J | 1 |
| Gilbert, P | 1 |
| Rampey, AH | 2 |
| Potvin, JH | 3 |
| Rush, AJ | 2 |
| kominguez, RA | 1 |
| Koran, LM | 4 |
| Shear, MK | 1 |
| Goodman, W | 2 |
| Genduso, LA | 2 |
| Mattes, JA | 1 |
| Hwang, MY | 2 |
| Martin, AM | 1 |
| Lindenmayer, JP | 1 |
| Stein, D | 2 |
| Hollander, E | 19 |
| Jackson, CW | 1 |
| Morton, WA | 1 |
| Lydiard, RB | 3 |
| Wright, S | 1 |
| Gatto, E | 1 |
| Pikielny, R | 1 |
| Micheli, F | 1 |
| Smith, DM | 1 |
| Levitte, SS | 1 |
| Cox, BJ | 1 |
| Swinson, RP | 1 |
| Morrison, B | 1 |
| Lee, PS | 1 |
| Tejera, CA | 1 |
| Mayerhoff, DJ | 1 |
| Safferman, AZ | 1 |
| Ramos-Lorenzi, JR | 1 |
| Wood, A | 1 |
| Bouvard, M | 1 |
| Dugas, M | 1 |
| Bodfish, JW | 1 |
| Madison, JT | 1 |
| Azari, NP | 1 |
| Pietrini, P | 2 |
| Horwitz, B | 1 |
| Pettigrew, KD | 1 |
| Rapoport, JL | 3 |
| Schapiro, MB | 2 |
| Josephson, SC | 1 |
| Levin, GM | 1 |
| DeVane, CL | 3 |
| Fawcett, J | 1 |
| Winokur, G | 1 |
| Beasley, CM | 2 |
| Faries, DE | 1 |
| Sayler, ME | 1 |
| Simeon, D | 2 |
| Steingard, S | 1 |
| Chengappa, KN | 1 |
| Baker, RW | 2 |
| Schooler, NR | 1 |
| DeCaria, CM | 3 |
| Saoud, JB | 1 |
| Klein, DF | 7 |
| Mundo, E | 1 |
| Ronchi, P | 1 |
| Bellodi, L | 1 |
| Montgomery, SA | 2 |
| McIntyre, A | 1 |
| Osterheider, M | 2 |
| Sarteschi, P | 1 |
| Zitterl, W | 3 |
| Zohar, J | 2 |
| Wood, AJ | 1 |
| McDougle, CJ | 6 |
| Price, LH | 5 |
| Bradley, SJ | 1 |
| Kulik, L | 1 |
| Dimitsopulos, T | 1 |
| Kurlan, R | 3 |
| Ninan, PT | 1 |
| Shelton, S | 1 |
| Sternlicht, HC | 1 |
| Ahmed, I | 1 |
| Dagincourt, PG | 1 |
| Miller, LG | 1 |
| Shader, RI | 1 |
| Como, PG | 2 |
| Deeley, C | 1 |
| McDermott, M | 1 |
| McDermott, MP | 1 |
| Grady, TA | 2 |
| Pigott, TA | 3 |
| L'Heureux, F | 2 |
| Hill, JL | 3 |
| Bernstein, SE | 2 |
| Murphy, DL | 9 |
| Patel, B | 1 |
| Tandon, R | 1 |
| Sichel, DA | 1 |
| Cohen, LS | 1 |
| Dimmock, JA | 1 |
| Rosenbaum, JF | 2 |
| Browne, M | 1 |
| Horn, E | 1 |
| Jones, TT | 1 |
| Jarry, JL | 1 |
| Vaccarino, FJ | 1 |
| Pryor, TL | 1 |
| Martin, RL | 1 |
| Roach, N | 1 |
| Zarate, CA | 1 |
| Kando, JC | 1 |
| Tohen, M | 1 |
| Weiss, MK | 1 |
| Cole, JO | 1 |
| Sandler, NH | 1 |
| el Mansari, M | 1 |
| Bouchard, C | 2 |
| Nijhawan, PK | 1 |
| Katz, G | 1 |
| Winter, S | 1 |
| Goldstein, DJ | 1 |
| Carrion, VG | 1 |
| Mueller, K | 1 |
| Maloney, A | 1 |
| López-Ibor, JJ | 1 |
| Saiz, J | 1 |
| Cottraux, J | 1 |
| Note, I | 1 |
| Viñas, R | 1 |
| Bourgeois, M | 1 |
| Hernández, M | 1 |
| Gómez-Pérez, JC | 1 |
| Kraus, RP | 1 |
| Nicholson, IR | 1 |
| Eapen, V | 1 |
| Trimble, MR | 2 |
| Robertson, MM | 1 |
| Altemus, M | 2 |
| Glowa, JR | 1 |
| Galliven, E | 1 |
| Leong, YM | 1 |
| Monteleone, P | 1 |
| Catapano, F | 1 |
| Tortorella, A | 1 |
| Di Martino, S | 1 |
| Maj, M | 1 |
| Filer, AD | 1 |
| Brockington, IF | 1 |
| Berk, M | 2 |
| Koopowitz, LF | 1 |
| Szabo, CP | 1 |
| Demal, U | 1 |
| Lenz, G | 2 |
| Zapotoczky, HG | 2 |
| Zitterl-Eglseer, K | 2 |
| Carpenter, LL | 1 |
| Epperson, CN | 2 |
| Bélanger, MC | 1 |
| Beauclair, L | 1 |
| Murphy, BE | 1 |
| Cain, JW | 1 |
| Thiemann, S | 1 |
| Albertini, RS | 1 |
| Phillips, KA | 1 |
| Guevremont, D | 1 |
| Oleshansky, MA | 1 |
| Labbate, LA | 1 |
| Bach, M | 1 |
| Aigner, M | 1 |
| Wever, C | 1 |
| Rey, JM | 1 |
| Strauss, WL | 2 |
| Layton, ME | 1 |
| Hayes, CE | 1 |
| Dager, SR | 2 |
| Koshes, RJ | 1 |
| Gangdev, PS | 1 |
| Kariuki, FN | 1 |
| Meltzer, H | 1 |
| Bastani, B | 1 |
| Jayathilake, K | 1 |
| Maes, M | 1 |
| Mhanna, MJ | 1 |
| Bennet, JB | 1 |
| Izatt, SD | 1 |
| Scahill, L | 5 |
| Vitulano, LA | 1 |
| Brenner, EM | 1 |
| Lynch, KA | 1 |
| King, RA | 4 |
| Minichiello, WE | 2 |
| Rauch, SL | 2 |
| Barr, LC | 1 |
| Anand, A | 1 |
| Molaie, M | 1 |
| Riddle, MA | 6 |
| Hardin, MT | 5 |
| Rasmusson, A | 1 |
| Makuch, RW | 1 |
| Gupta, S | 1 |
| Austin, R | 1 |
| Black, DW | 1 |
| Flament, MF | 1 |
| Bisserbe, JC | 1 |
| Puig, A | 1 |
| Peterson, BS | 1 |
| Cohen, DJ | 3 |
| Gross, S | 1 |
| Islam, N | 1 |
| Schmeidler, J | 1 |
| Corá-Locatelli, G | 2 |
| Greenberg, BD | 3 |
| Martin, JD | 2 |
| Attia, E | 1 |
| Haiman, C | 1 |
| Walsh, BT | 1 |
| Flater, SR | 1 |
| Bosch, X | 1 |
| Vera, M | 1 |
| Ackerman, DL | 2 |
| Greenland, S | 2 |
| Bystritsky, A | 2 |
| Go, FS | 1 |
| Malley, EE | 1 |
| Birmaher, B | 1 |
| Rosenberg, DR | 1 |
| Monasterio, E | 1 |
| Marshall, TD | 1 |
| Wynchank, D | 1 |
| Martin, J | 1 |
| Potenza, MN | 1 |
| Wasylink, S | 1 |
| Longhurst, JG | 1 |
| Cookson, J | 1 |
| Duffett, R | 1 |
| Galli, VB | 1 |
| Raute, NJ | 1 |
| McConville, BJ | 1 |
| McElroy, SL | 1 |
| Benjamin, J | 1 |
| Keuler, D | 1 |
| Huang, SJ | 1 |
| Golwyn, DH | 1 |
| Sevlie, CP | 1 |
| Bergqvist, PB | 1 |
| Goldsmith, TB | 1 |
| Keck, PE | 1 |
| Mahendran, R | 1 |
| Mottard, JP | 1 |
| de la Sablonnière, JF | 1 |
| Trappler, B | 1 |
| Meszaros, K | 1 |
| Hornik, K | 1 |
| Twaroch, T | 1 |
| Dossenbach, M | 1 |
| Thomsen, PH | 1 |
| Mikkelsen, HU | 1 |
| Mataix-Cols, D | 2 |
| Manzo, PA | 1 |
| Gorfinkle, KS | 1 |
| Granana, N | 1 |
| Tuchman, RF | 1 |
| Millet, B | 1 |
| Touitou, Y | 1 |
| Poirier, MF | 1 |
| Bourdel, MC | 1 |
| Amado, I | 1 |
| Hantouche, EG | 1 |
| Bogdan, A | 1 |
| Olié, JP | 1 |
| Todorov, C | 1 |
| Freeston, MH | 1 |
| Borgeat, F | 1 |
| Reus, VI | 1 |
| Rawitscher, L | 1 |
| Velazquez, L | 1 |
| Ward-Chene, L | 1 |
| Loosigian, SR | 1 |
| Ringold, AL | 1 |
| Elliott, MA | 1 |
| Neziroglu, F | 1 |
| Yaryura-Tobias, JA | 2 |
| Walz, J | 1 |
| McKay, D | 1 |
| Romano, S | 1 |
| Tamura, R | 2 |
| Gonzales, J | 1 |
| De Marchi, N | 1 |
| Daniele, F | 1 |
| Ragone, MA | 1 |
| Marusic, A | 1 |
| Farmer, A | 1 |
| Harel, Z | 1 |
| Hallett, J | 1 |
| Riggs, S | 1 |
| Vaz, R | 1 |
| Kiessling, L | 1 |
| Joel, D | 1 |
| Avisar, A | 1 |
| Garland, EJ | 1 |
| Baerg, EA | 1 |
| Hoog, SL | 1 |
| Heiligenstein, JH | 1 |
| Ricardi, RK | 1 |
| Kluszynski, S | 1 |
| Jacobson, JG | 1 |
| Pifarre, J | 1 |
| Torres, L | 1 |
| Salgado, P | 1 |
| Al-Sughayir, MA | 1 |
| Ferris, CF | 1 |
| Rasmussen, MF | 1 |
| Messenger, T | 1 |
| Koppel, G | 1 |
| Kane, JM | 1 |
| Neel, JL | 1 |
| Stevens, VM | 1 |
| Stewart, JE | 1 |
| Bergeron, R | 1 |
| Ravindran, AV | 1 |
| Chaput, Y | 1 |
| Goldner, E | 1 |
| Swinson, R | 1 |
| van Ameringen, MA | 1 |
| Austin, C | 1 |
| Hadrava, V | 1 |
| Unis, AS | 1 |
| Cowan, C | 1 |
| Dawson, G | 1 |
| Diler, RS | 1 |
| Yolga, AY | 1 |
| Avci, A | 1 |
| Manceaux, A | 1 |
| Ryland, DH | 1 |
| Kriete, M | 1 |
| Anthony, DT | 1 |
| Schneier, FR | 5 |
| Fallon, BA | 3 |
| Pach, J | 1 |
| Cohen, L | 1 |
| DeCaria, C | 4 |
| Trungold-Apter, S | 1 |
| Islam, M | 1 |
| Renshaw, PF | 1 |
| Guimaraes, AR | 1 |
| Pearlman, JD | 1 |
| Flood, JG | 1 |
| Puopolo, PR | 1 |
| Clancy, K | 1 |
| Gonzalez, RG | 1 |
| Maruno, CA | 1 |
| Hart, LL | 1 |
| Anderson, GM | 3 |
| Ort, SI | 1 |
| Smith, JC | 1 |
| George, MS | 2 |
| Gunzberger, DW | 1 |
| Martinez, D | 1 |
| Warnock, JK | 1 |
| Kestenbaum, T | 1 |
| Carrasco, JL | 1 |
| Judd, F | 1 |
| Ellen, S | 1 |
| Norman, T | 1 |
| Leznoff, A | 1 |
| Binkley, KE | 1 |
| Joffee, RT | 1 |
| Levitt, A | 1 |
| Richter, MA | 1 |
| Galynker, I | 1 |
| McQuistion, H | 1 |
| Kahn, RS | 1 |
| Friedman, M | 1 |
| Vieta, E | 1 |
| Bernardo, M | 1 |
| Baxter, LR | 1 |
| Schwartz, JM | 1 |
| Bergman, KS | 1 |
| Szuba, MP | 1 |
| Guze, BH | 1 |
| Mazziotta, JC | 1 |
| Alazraki, A | 1 |
| Selin, CE | 1 |
| Ferng, HK | 1 |
| Munford, P | 1 |
| Rettew, DC | 1 |
| Goldberger, EL | 1 |
| Rapoport, SI | 1 |
| Grady, CL | 1 |
| Winchel, RM | 1 |
| Jones, JS | 1 |
| Stanley, B | 1 |
| Molcho, A | 1 |
| Stanley, M | 1 |
| Kindler, S | 1 |
| Masica, DN | 1 |
| Wheadon, DE | 1 |
| Dornseif, BE | 1 |
| Deas-Nesmith, D | 1 |
| Brewerton, TD | 1 |
| Schenck, CH | 1 |
| Mahowald, MW | 1 |
| Kim, SW | 2 |
| O'Connor, KA | 1 |
| Hurwitz, TD | 1 |
| Cook, EH | 2 |
| Rowlett, R | 1 |
| Jaselskis, C | 1 |
| Leventhal, BL | 2 |
| Hoh, A | 1 |
| Schulte, HM | 1 |
| Müller, T | 1 |
| Gitow, A | 1 |
| Liebowitz, M | 1 |
| Casey, DA | 1 |
| Pato, MT | 3 |
| Ananth, J | 1 |
| Elmishaugh, A | 1 |
| Javitch, JA | 1 |
| Kaye, WH | 1 |
| Weltzin, TE | 1 |
| Hsu, LK | 1 |
| Bulik, CM | 1 |
| Alarcon, RD | 1 |
| Johnson, BR | 1 |
| Lucas, JP | 1 |
| Solyom, L | 1 |
| Solyom, C | 1 |
| Ledwidge, B | 1 |
| Yadin, E | 1 |
| Friedman, E | 1 |
| Bridger, WH | 1 |
| Viswanathan, R | 1 |
| Paradis, C | 1 |
| Hoehn-Saric, R | 2 |
| Pearlson, GD | 2 |
| Harris, GJ | 2 |
| Machlin, SR | 2 |
| Camargo, EE | 2 |
| Dorval, GS | 1 |
| Meinzer, AE | 1 |
| Koizumi, H | 1 |
| Steiner, W | 2 |
| Howland, RH | 1 |
| Austin, LS | 1 |
| Zealberg, JJ | 1 |
| Alessi, N | 1 |
| Bos, T | 1 |
| Tamimi, RR | 1 |
| Mavissakalian, MR | 1 |
| Mullen, L | 1 |
| Skodol, A | 1 |
| Deckert, DW | 1 |
| Malone, DA | 1 |
| Buttolph, L | 3 |
| Dysken, MW | 1 |
| Fishbain, DA | 1 |
| Goldberg, M | 1 |
| Matthews, P | 1 |
| Quinn, D | 1 |
| Marcoux, GS | 1 |
| Falkenberg, K | 1 |
| Cox, CS | 1 |
| Chappell, PB | 1 |
| Lombroso, P | 1 |
| Perilstein, RD | 1 |
| Lipper, S | 1 |
| Friedman, LJ | 1 |
| Gully, R | 1 |
| Nitescu, A | 1 |
| Suckow, RF | 1 |
| Gorman, JM | 2 |
| Gross, MD | 1 |
| Stokes, PE | 1 |
| Lee, S | 1 |
| Bihari, K | 1 |
| Kirschen, H | 1 |
| Ninan, P | 1 |
| Mosberg, HJ | 1 |
| Emmanuel, NP | 1 |
| Ballenger, JC | 1 |
| Frenkel, A | 1 |
| Rosenthal, J | 1 |
| Nezu, A | 1 |
| Winston, A | 1 |
| Schneier, HA | 1 |
| Fairbanks, J | 4 |
| Fallon, B | 1 |
| Insel, TR | 1 |
| Hyman, S | 1 |
| Holland, A | 2 |
| Summergrad, P | 1 |
| Seymour, R | 1 |
| Markovitz, PJ | 1 |
| Stagno, SJ | 1 |
| Calabrese, JR | 1 |
| Staab, JP | 1 |
| Yerkes, SA | 1 |
| Cheney, EM | 1 |
| Clayton, AH | 1 |
| Grover, GN | 1 |
| Tolliver, TJ | 1 |
| Campeas, RB | 1 |
| Papp, LA | 2 |
| Hatterer, JA | 1 |
| Sandberg, D | 2 |
| Tanquary, J | 1 |
| Masand, P | 1 |
| Simeon, JG | 1 |
| Thatte, S | 1 |
| Wiggins, D | 1 |
| DeMaso, DR | 1 |
| Hunter, TA | 1 |
| King, R | 1 |
| Woolston, JL | 2 |
| Stout, RJ | 1 |
| Campeas, R | 3 |
| Bianchi, MD | 1 |
| Terry, EJ | 1 |
| Heller, W | 1 |
| Lane, RD | 1 |
| Johnston, H | 1 |
| Levine, R | 1 |
| Hoffman, JS | 1 |
| Knepple, ED | 1 |
| Kenin, M | 1 |
| Saran, A | 1 |
| Halaris, A | 1 |
| Lipinski, JF | 1 |
| Mallya, G | 1 |
| Zimmerman, P | 1 |
| Pope, HG | 1 |
| Swerdlow, NR | 1 |
| Andia, AM | 1 |
| Jacobson, AF | 1 |
| de la Gandara, J | 1 |
| Goldstein, BJ | 1 |
| Steinbook, RM | 1 |
| Winchel, R | 1 |
| Klumker, A | 1 |
| Schneier, F | 1 |
| Hatterer, J | 1 |
| Papp, L | 2 |
| Davies, S | 1 |
| Stein, M | 1 |
| Kline, MD | 1 |
| Brown, N | 1 |
| Dzubinski, D | 1 |
| Jetmalani, AN | 1 |
| Law, Y | 1 |
| Granet, RB | 1 |
| Fontaine, R | 5 |
| Primeau, F | 1 |
| Jacob, RG | 2 |
| Griffin, S | 1 |
| Himmelhoch, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Randomized Open Trial for Any Patient.[NCT00680602] | Phase 4 | 158 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Narrative Therapy for Treatment-Resistant Obsessive-Compulsive Disorder[NCT04154085] | 14 participants (Actual) | Interventional | 2021-01-02 | Completed | |||
| A Double Blind, Randomized, Placebo-Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin (FCT)[NCT02410902] | Phase 3 | 190 participants (Actual) | Interventional | 2015-05-13 | Completed | ||
| An Open-Label Extension Study of CM-AT for the Treatment of Children With Autism With All Levels of Fecal Chymotrypsin[NCT02649959] | Phase 3 | 405 participants (Anticipated) | Interventional | 2015-10-31 | Active, not recruiting | ||
| Pharmacological Augmentation Strategies for Obsessive Compulsive Disorder Patients Non-respondent to First Line Medication Treatment: a Double Blind Placebo Controlled Study[NCT00466609] | Phase 4 | 54 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Clinical, Neurocognitive and Neuroimaging Variables Associated With Response to Treatment in Patients With OCD[NCT03993535] | Phase 4 | 250 participants (Actual) | Interventional | 2018-10-10 | Active, not recruiting | ||
| Neurobiology/Treatment of Obsessive-Compulsive Disorder[NCT00000373] | Phase 4 | 74 participants (Actual) | Interventional | 1992-09-30 | Completed | ||
| An Open-Label Trial of Epidiolex in the Treatment of Obsessive Compulsive Disorder and Related Disorders: Proof of Concept Study[NCT04978428] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-04-14 | Recruiting | ||
| Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial.[NCT00564564] | Phase 4 | 21 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| The Role of Serotonin in Compulsive Behavior in Humans: Underlying Brain Mechanisms[NCT04336228] | Phase 4 | 48 participants (Anticipated) | Interventional | 2020-04-01 | Recruiting | ||
| Augment in Treatment-resistent Obsessive-compulsive Disorder: an Open-label Trial[NCT00590642] | 30 participants (Anticipated) | Observational | 2006-04-30 | Completed | |||
| Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308] | Phase 2 | 20 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Escitalopram for the Treatment of Self-Injurious Skin Picking[NCT00115011] | Phase 4 | 30 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| Studies of Cortical Excitability in Obsessive-Compulsive Disorder, Related Disorder and Healthy Volunteers Using Paired-Pulse Transcranial Magnetic Stimulation[NCT00029068] | 145 participants | Observational | 2002-01-31 | Completed | |||
| Cerebral Structure and Function Before and After Pharmacological and Psychological Treatment for PTSD[NCT00069225] | 95 participants | Observational | 2003-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary outcome measurements to determine efficacy of treatment with CM-AT versus Placebo for changes in the Aberrant Behavior Checklist (ABC) - Community sub scale for Irritability/Agitation (ABC-I) between baseline (subject's initial measurement) and Week 12/Termination (subject's final measurement) visit. Participants were between 3 through to 6 years old inclusive and took 900mg CM-AT or Placebo three times daily. The ABC-I is one of five discrete sub scales measured by the ABC. The scale range is 0-45. A higher score reflects higher severity of symptoms (irritability). Scores are obtained via Parent Rated Questionnaire. Parents respond to a series of questions on a scale directly into an electronic data capture system (EDC), responding: 0 = not at all a problem 1 = the behavior is a problem but slight in degree 2 = the problem is moderately serious 3 = the problem is severe in degree. The score was automatically calculated by the EDC. (NCT02410902)
Timeframe: Screening through Week 12/Termination
| Intervention | units on a scale (Mean) |
|---|---|
| CM-AT | -8.0 |
| Placebo | -5.5 |
Secondary outcome measurements to determine efficacy of treatment with CM-AT versus Placebo for changes in the Aberrant Behavior Checklist- Community (ABC) sub scale for Lethargy / Social Withdrawal (ABC-L) between baseline (subject's initial measurement) and Week 12/Termination (subject's final measurement) visit. Participants were between 3 through to 6 years old inclusive and took 900mg CM-AT or Placebo three times daily. The ABC-L is one of five discrete sub scales measured by the ABC. The scale range is 0-48. A higher score reflects higher severity of symptoms (lethargy). Scores are obtained via Parent Rated Questionnaire. Parents respond to a series of questions on a scale directly into an electronic data capture system (EDC), responding: 0 = not at all a problem 1 = the behavior is a problem but slight in degree 2 = the problem is moderately serious 3 = the problem is severe in degree. (NCT02410902)
Timeframe: Screening through Week 12/Termination.
| Intervention | units on a scale (Mean) |
|---|---|
| CM-AT | -7.9 |
| Placebo | -6.6 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 2 |
| Sham | 8 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 1 |
| Sham | 0 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56.5 |
| Sham | 63.8 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56 |
| Sham | 59.8 |
Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 29.5 |
| Sham | 31.5 |
43 reviews available for fluoxetine and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Fluoxetine in acute treatment of children and adolescents with obsessive-compulsive disorder: a systematic review and meta-analysis.
Topics: Adolescent; Child; Citalopram; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Prospective Studie | 2020 |
Review of epidemiology, clinical presentation, diagnosis, and treatment of common primary psychiatric causes of cutaneous disease.
Topics: Antipsychotic Agents; Body Dysmorphic Disorders; Cognitive Behavioral Therapy; Fluoxetine; Humans; M | 2018 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Child Development Disorders, Pervasive; Citalopram; Fe | 2013 |
[Use of psychotropic drugs in children].
Topics: Adolescent; Age Factors; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Dis | 2008 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Hum | 2010 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Hum | 2010 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Hum | 2010 |
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD).
Topics: Adult; Age Factors; Autistic Disorder; Child; Citalopram; Fenfluramine; Fluoxetine; Fluvoxamine; Hum | 2010 |
[The mental disorder and obsessive-compulsive spectrum disorders in childhood ].
Topics: Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Clomipramine; Cognitive Behavio | 2011 |
[Obsessive-compulsive disorders in general practice. How the obsessive-compulsive neurotic is revealed by skin and hair].
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Age | 2003 |
[Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents].
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents, Second-Generation; Case-Control Studies; Chil | 2006 |
Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder.
Topics: Clomipramine; Fluoxetine; Humans; Meta-Analysis as Topic; Obsessive-Compulsive Disorder; Randomized | 2007 |
Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placebo.
Topics: Adolescent; Aggression; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major; | 2007 |
Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II.
Topics: Adolescent; Alprazolam; Anticonvulsants; Antipsychotic Agents; Anxiety, Separation; Bipolar Disorder | 1995 |
[Drug treatment of obsessive-compulsive disorders--a comparative study of the effectiveness of clomipramine and fluoxetine].
Topics: Clomipramine; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Treatment Outcome | 1995 |
Current knowledge of medications for the treatment of childhood anxiety disorders.
Topics: Adolescent; Age of Onset; Anti-Anxiety Agents; Anxiety Disorders; Child; Clomipramine; Fluoxetine; H | 1995 |
Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.
Topics: 1-Naphthylamine; Adolescent; Adult; Clomipramine; Double-Blind Method; Female; Fluoxetine; Fluvoxami | 1995 |
Childhood movement disorders and obsessive compulsive disorder.
Topics: Antipsychotic Agents; Child; Chorea; Clinical Trials as Topic; Clomipramine; Comorbidity; Female; Fl | 1994 |
Psychosocial treatment for obsessive-compulsive disorder.
Topics: Adult; Antidepressive Agents; Behavior Therapy; Combined Modality Therapy; Fluoxetine; Humans; Male; | 1994 |
Management of treatment-refractory obsessive compulsive disorder patients.
Topics: Antipsychotic Agents; Behavior Therapy; Clomipramine; Clonazepam; Combined Modality Therapy; Control | 1994 |
Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: a meta-analysis.
Topics: Behavior Therapy; Clomipramine; Combined Modality Therapy; Fluoxetine; Humans; Obsessive-Compulsive | 1993 |
Pharmacotherapy of obsessive compulsive disorder--experience with fluoxetine.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Fluoxetine; Humans; | 1993 |
Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders.
Topics: Antidepressive Agents, Tricyclic; Bulimia; Clinical Trials as Topic; Depressive Disorder; Double-Bli | 1993 |
The pharmacotherapy of obsessive-compulsive disorder.
Topics: 1-Naphthylamine; Buspirone; Clomipramine; Desipramine; Fluoxetine; Fluvoxamine; Humans; Obsessive-Co | 1993 |
Eating disorder and obsessive-compulsive disorder: neurochemical and phenomenological commonalities.
Topics: Anorexia Nervosa; Bulimia; Clomipramine; Comorbidity; Female; Fluoxetine; Humans; Male; Obsessive-Co | 1996 |
Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience.
Topics: Adolescent; Adult; Age Factors; Child; Clinical Trials as Topic; Depressive Disorder; Female; Fluoxe | 1996 |
Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline?
Topics: 1-Naphthylamine; Adolescent; Adult; Bipolar Disorder; Depressive Disorder; Drug Tolerance; Female; F | 1996 |
A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.
Topics: 1-Naphthylamine; Adult; Aged; Antidepressive Agents; Buspirone; Child; Clomipramine; Clonazepam; Cos | 1996 |
Pharmacologic treatment of obsessive-compulsive disorder: comparative studies.
Topics: 1-Naphthylamine; Adult; Antidepressive Agents; Clinical Trials as Topic; Clomipramine; Fluoxetine; F | 1997 |
The treatment of Tourette's syndrome: multimodal, developmental intervention.
Topics: Adaptation, Psychological; Adolescent; Adrenergic Agonists; Adult; Age Factors; Antidepressive Agent | 1998 |
Fluoxetine: therapeutic and undesirable effects.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Bulimia; Child; Drug Interactions; Fluo | 1998 |
On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?
Topics: Clomipramine; Double-Blind Method; Expert Testimony; Fluoxetine; Fluvoxamine; Guidelines as Topic; H | 2000 |
Obsessive-compulsive disorder: identification, neurobiology, and treatment.
Topics: Adult; Behavior Therapy; Child; Combined Modality Therapy; Female; Fluoxetine; Follow-Up Studies; Hu | 2002 |
Fluvoxamine in the treatment of obsessive compulsive disorder.
Topics: Combined Modality Therapy; Depressive Disorder; Desensitization, Psychologic; Fluoxetine; Humans; Ob | 1992 |
Buspirone in obsessive-compulsive disorder.
Topics: Adult; Buspirone; Clinical Trials as Topic; Clomipramine; Drug Therapy, Combination; Female; Fluoxet | 1992 |
Serotonergic antidepressants and their efficacy in obsessive compulsive disorder.
Topics: Clomipramine; Double-Blind Method; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Randomized Con | 1992 |
The role of serotonin and dopamine in the pathophysiology of obsessive compulsive disorder.
Topics: Brain; Clomipramine; Dopamine; Fluoxetine; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Serot | 1992 |
Serotonergic probes in obsessive compulsive disorder.
Topics: Brain; Clomipramine; Fluoxetine; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Receptors, Sero | 1992 |
Pharmacotherapy of obsessive compulsive disorder.
Topics: 1-Naphthylamine; Antidepressive Agents; Clomipramine; Depressive Disorder; Fluoxetine; Fluvoxamine; | 1992 |
Obsessive-compulsive disorder. Characteristic features, pharmacologic management.
Topics: Clomipramine; Fluoxetine; Humans; Obsessive-Compulsive Disorder | 1992 |
Obsessive-compulsive disorder.
Topics: Clomipramine; Fluoxetine; Fluvoxamine; Humans; Obsessive-Compulsive Disorder | 1991 |
The changing horizon in the treatment of depression: scientific/clinical publication overview.
Topics: Adolescent; Ambulatory Care; Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Dep | 1991 |
New pharmacologic approaches to obsessive compulsive disorder.
Topics: Behavior Therapy; Clinical Trials as Topic; Clomipramine; Combined Modality Therapy; Fluoxetine; Flu | 1990 |
Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy.
Topics: Clomipramine; Fluoxetine; Humans; Meta-Analysis as Topic; Obsessive-Compulsive Disorder; Psychiatric | 1990 |
A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory.
Topics: 1-Naphthylamine; Adult; Ambulatory Care; Clinical Trials as Topic; Clomipramine; Double-Blind Method | 1990 |
Treatment of body-dysmorphic disorder with serotonin reuptake blockers.
Topics: Adult; Body Image; Clomipramine; Diagnosis, Differential; Female; Fluoxetine; Humans; Male; Middle A | 1989 |
94 trials available for fluoxetine and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial.
Topics: Adolescent; Anxiety; Autism Spectrum Disorder; Child; Confounding Factors, Epidemiologic; Female; Fl | 2019 |
The safety and efficacy of transcranial direct current stimulation as add-on therapy to fluoxetine in obsessive-compulsive disorder: a randomized, double-blind, sham-controlled, clinical trial.
Topics: Double-Blind Method; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Transcranial Direct Current | 2020 |
Effect of crocin versus fluoxetine in treatment of mild to moderate obsessive-compulsive disorder: A double blind randomized clinical trial.
Topics: Carotenoids; Double-Blind Method; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Psychiatric Sta | 2021 |
Dissecting the Yale-Brown Obsessive-Compulsive Scale severity scale to understand the routes for symptomatic improvement in obsessive-compulsive disorder.
Topics: Adult; Female; Fluoxetine; Humans; Male; Obsessive Behavior; Obsessive-Compulsive Disorder; Psychiat | 2017 |
Adaptive treatment strategies for children and adolescents with Obsessive-Compulsive Disorder: A sequential multiple assignment randomized trial.
Topics: Adolescent; Child; Cognitive Behavioral Therapy; Female; Fluoxetine; Humans; Male; Obsessive-Compuls | 2018 |
Efficacy and tolerability of adjunctive gabapentin and memantine in obsessive compulsive disorder: Double-blind, randomized, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Dopamine Agents; Double-Blind Method; Female; Fluoxetine; Gabapentin; Humans | 2018 |
Double Blind Controlled Study of Adding Folic Acid to Fluoxetine in the Treatment of OCD.
Topics: Double-Blind Method; Drug Therapy, Combination; Fluoxetine; Folic Acid; Humans; Obsessive-Compulsive | 2019 |
Can early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making.
Topics: Adolescent; Adult; Aged; Decision Making; Female; Fluoxetine; Follow-Up Studies; Humans; Logistic Mo | 2013 |
The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsychotic Age | 2014 |
Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder.
Topics: Adolescent; Anxiety Disorders; Child; Depressive Disorder, Major; Dose-Response Relationship, Drug; | 2014 |
Child-focused treatment of pediatric OCD affects parental behavior and family environment.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Anxiety; Child; Cognitive Behavioral Th | 2015 |
Combination of CBT with fluoxetine works better for obsessive-compulsive disorder.
Topics: Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Fluoxetine; Humans; Male; Ob | 2012 |
A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD).
Topics: Adolescent; Child; Citalopram; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind M | 2009 |
Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine.
Topics: Adolescent; Adult; Aged; Checklist; Depressive Disorder, Major; Double-Blind Method; Drug Administra | 2010 |
Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of Obsessive-Compulsive Disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Double-Blind Method; Female; Fluoxetine; Humans; Ma | 2010 |
A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder.
Topics: Adult; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Interview, Psycho | 2010 |
A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blin | 2011 |
Cognitive behavior therapy in medication non-responders with obsessive-compulsive disorder: a prospective 1-year follow-up study.
Topics: Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Fluoxetine; Follow-Up Studie | 2011 |
Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial.
Topics: Adolescent; Adult; Aged; Cognitive Behavioral Therapy; Female; Fluoxetine; Follow-Up Studies; Humans | 2012 |
A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Clomipramine; Dibenzothiazepines; Double-Blind Method; Drug | 2011 |
Gray matter volumes in obsessive-compulsive disorder before and after fluoxetine or cognitive-behavior therapy: a randomized clinical trial.
Topics: Adult; Brain; Cognitive Behavioral Therapy; Female; Fluoxetine; Humans; Image Processing, Computer-A | 2012 |
Evaluation of oral zinc sulfate effect on obsessive-compulsive disorder: a randomized placebo-controlled clinical trial.
Topics: Administration, Oral; Adult; Dietary Supplements; Double-Blind Method; Drug Therapy, Combination; Fe | 2012 |
Neuropsychological predictors of response to randomized treatment in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Aged; Cognitive Behavioral Therapy; Female; Fluoxetine; Humans; Intelligence Test | 2012 |
Differential prefrontal gray matter correlates of treatment response to fluoxetine or cognitive-behavioral therapy in obsessive-compulsive disorder.
Topics: Adult; Atrophy; Cognitive Behavioral Therapy; Female; Fluoxetine; Humans; Male; Nerve Fibers, Unmyel | 2013 |
Clinical predictors of long-term outcome in obsessive-compulsive disorder.
Topics: Adult; Age Factors; Age of Onset; Cognitive Behavioral Therapy; Depressive Disorder; Female; Fluoxet | 2013 |
Efficacy of combination of fluoxetine and cognitive behavioral therapy and fluoxetine alone for the treatment of obsessive compulsive disorder.
Topics: Administration, Oral; Adult; Bangladesh; Capsules; Cognitive Behavioral Therapy; Combined Modality T | 2013 |
Fluoxetine in children and adolescents with OCD: a placebo-controlled trial.
Topics: Adolescent; Child; Dose-Response Relationship, Drug; Female; Fluoxetine; Follow-Up Studies; Humans; | 2002 |
Polymorphisms of DRD4 and DRD3 and risk of avoidant and obsessive personality traits and disorders.
Topics: Adult; Alleles; Character; Exons; Exploratory Behavior; Female; Fluoxetine; Genotype; Humans; Male; | 2003 |
Neuropsychological performance of OCD patients before and after treatment with fluoxetine: evidence for persistent cognitive deficits.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Cognition; Female; Fluoxetine; Humans; | 2003 |
A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug | 2004 |
Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors.
Topics: Adult; Ambulatory Care; Citalopram; Clomipramine; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies | 2004 |
Clinical predictors of early fluoxetine treatment response in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Age Factors; Chronic Disease; Dose-Response Relationship, Drug; Drug Administrati | 2006 |
Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?
Topics: Administration, Oral; Adolescent; Adult; Amines; Analysis of Variance; Anti-Anxiety Agents; Cyclohex | 2008 |
Predictors of drug treatment response in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Age of Onset; Clomipramine; Comorbidity; Fluoxetine; Follow-Up Studies; Humans; M | 1995 |
Predictors of drug treatment response in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Age of Onset; Clomipramine; Comorbidity; Fluoxetine; Follow-Up Studies; Humans; M | 1995 |
Predictors of drug treatment response in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Age of Onset; Clomipramine; Comorbidity; Fluoxetine; Follow-Up Studies; Humans; M | 1995 |
Predictors of drug treatment response in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Age of Onset; Clomipramine; Comorbidity; Fluoxetine; Follow-Up Studies; Humans; M | 1995 |
[The psychopharmacotherapy of anxious-depressive states (the interrelationship of the structure of the comorbidity to the choice of drug therapy)].
Topics: Adult; Alprazolam; Anxiety; Comorbidity; Depression; Double-Blind Method; Female; Fluoxetine; Humans | 1994 |
Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.
Topics: Adolescent; Adult; Aged; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admin | 1994 |
A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Dose-Response Relationship, Drug; Double-Blind Method; Dru | 1994 |
Diagnosis and fluoxetine treatment of compulsive behavior disorder of adults with mental retardation.
Topics: Adult; Aggression; Female; Fluoxetine; Humans; Intellectual Disability; Male; Obsessive-Compulsive D | 1993 |
A pilot study of biological predictors of treatment outcome in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Ambulatory Care; Clomipramine; Dose-Response Relationship, Drug; Double-Blind Met | 1993 |
A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Obsessi | 1993 |
A pilot controlled study of fluoxetine for obsessive-compulsive symptoms in children with Tourette's syndrome.
Topics: Adolescent; Child; Double-Blind Method; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Pil | 1993 |
Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder.
Topics: Adult; Anxiety Disorders; Buspirone; Depressive Disorder; Double-Blind Method; Drug Therapy, Combina | 1993 |
Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Clomipramine; Dou | 1996 |
The use of fluoxetine in Gilles de la Tourette syndrome and obsessive compulsive behaviours: preliminary clinical experience.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Child, Preschool; Family Practice; Fema | 1996 |
Plasma melatonin and cortisol circadian patterns in patients with obsessive-compulsive disorder before and after fluoxetine treatment.
Topics: Adult; Circadian Rhythm; Female; Fluoxetine; Humans; Hydrocortisone; Male; Melatonin; Middle Aged; O | 1995 |
Obsessive compulsive disorder and depression--first results of a prospective study on 74 patients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Cro | 1996 |
Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration | 1996 |
Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs).
Topics: Adult; Clomipramine; Dose-Response Relationship, Drug; Female; Fluoxetine; Fluvoxamine; Follow-Up St | 1996 |
19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Aged; Brain; Brain Chemistry; Drug Administration Schedule; Fluorine; Fluoxetine; | 1997 |
Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder.
Topics: 5-Hydroxytryptophan; Adult; Age Factors; Antidepressive Agents, Second-Generation; Antidepressive Ag | 1997 |
Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder.
Topics: Adult; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Monoamine Oxidase Inhibitors; | 1997 |
Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
Topics: 1-Naphthylamine; Adrenergic Uptake Inhibitors; Adult; Clomipramine; Desipramine; Double-Blind Method | 1997 |
Fluoxetine has no marked effect on tic symptoms in patients with Tourette's syndrome: a double-blind placebo-controlled study.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Child; Cross-Over Studies; Double-Blind Method; Female; | 1997 |
A double-blind trial of fluoxetine in pathologic skin picking.
Topics: Adult; Confounding Factors, Epidemiologic; Disruptive, Impulse Control, and Conduct Disorders; Doubl | 1997 |
Does fluoxetine augment the inpatient treatment of anorexia nervosa?
Topics: Adolescent; Adult; Anorexia Nervosa; Body Weight; Combined Modality Therapy; Depressive Disorder; Do | 1998 |
Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Double-Blind Method; Female; Fluoxetine; Humans; Ma | 1998 |
Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Bipolar Disorder; Child; Depressive Disorder; | 1998 |
Fluoxetine treatment of acral lick dermatitis in dogs: a placebo-controlled randomized double blind trial.
Topics: Animals; Antidepressive Agents, Second-Generation; Dermatitis; Disease Models, Animal; Dog Diseases; | 1998 |
Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Drug T | 1998 |
Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients.
Topics: Adult; Behavior; Double-Blind Method; Female; Fluoxetine; Humans; Male; Metergoline; Middle Aged; Ob | 1998 |
Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder.
Topics: Adult; Austria; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoxetine; Humans; M | 1999 |
The addition of buspirone to SSRI in the treatment of adolescent obsessive-compulsive disorder. A study of six cases.
Topics: Adolescent; Adult; Buspirone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; F | 1999 |
Side effects as predictors of drug response in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Anxiety; Clomipramine; Dose-Response Relationship, Drug; Ejaculation; Female; Flu | 1999 |
Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.
Topics: Ambulatory Care; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug Administration Schedu | 1999 |
On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?
Topics: Clomipramine; Double-Blind Method; Expert Testimony; Fluoxetine; Fluvoxamine; Guidelines as Topic; H | 2000 |
Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
Topics: Adult; Benzodiazepines; Drug Administration Schedule; Drug Therapy, Combination; Fluoxetine; Humans; | 2000 |
The effect of fluvoxamine and behavior therapy on children and adolescents with obsessive-compulsive disorder.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Behavior Therapy; Child; Combined Modality The | 2000 |
Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Double-Blind Method; Female; Fluo | 2001 |
Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.
Topics: Adolescent; Analysis of Variance; Child; Consumer Product Safety; Double-Blind Method; Female; Fluox | 2001 |
Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy.
Topics: Adolescent; Adult; Age of Onset; Ambulatory Care; Behavior Therapy; Clomipramine; Combined Modality | 2001 |
Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study.
Topics: Adolescent; Adult; Female; Fluoxetine; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Psy | 2002 |
Drug treatment of canine acral lick. An animal model of obsessive-compulsive disorder.
Topics: 1-Naphthylamine; Animals; Clomipramine; Dermatitis; Desipramine; Disease Models, Animal; Dog Disease | 1992 |
Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.
Topics: Adolescent; Child; Double-Blind Method; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive Disor | 1992 |
Serotonergic antidepressants and their efficacy in obsessive compulsive disorder.
Topics: Clomipramine; Double-Blind Method; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Randomized Con | 1992 |
Clinical characteristics of trichotillomania and its response to fluoxetine.
Topics: Adult; Anxiety; Comorbidity; Depressive Disorder; Female; Fluoxetine; Humans; Male; Middle Aged; Obs | 1992 |
Low-dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania.
Topics: Adult; Clomipramine; Comorbidity; Dopamine; Drug Therapy, Combination; Female; Fluoxetine; Humans; M | 1992 |
Fluoxetine: no association with suicidality in obsessive-compulsive disorder.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoxetine; Humans; Male; Midd | 1992 |
Long-term fluoxetine treatment decreases 5-HT1A receptor responsivity in obsessive-compulsive disorder.
Topics: Adrenocorticotropic Hormone; Adult; Anti-Anxiety Agents; Behavior; Body Temperature Regulation; Doub | 1991 |
An open trial of fluoxetine in patients with anorexia nervosa.
Topics: Adolescent; Adult; Ambulatory Care; Anorexia Nervosa; Body Weight; Bulimia; Female; Fluoxetine; Foll | 1991 |
Obsessive compulsive disorder, depression, and fluoxetine.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder; Drug Therapy, Combination; Fema | 1991 |
Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder.
Topics: Buspirone; Drug Therapy, Combination; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Pilot Proje | 1991 |
Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder.
Topics: Adult; Arousal; Brain; Female; Fluoxetine; Humans; Hydrocortisone; Male; Obsessive-Compulsive Disord | 1991 |
An open-label trial of fluoxetine for obsessive-compulsive disorder in Gilles de la Tourette's syndrome.
Topics: Adolescent; Child; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Psychiatric Stat | 1991 |
Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy.
Topics: Clomipramine; Fluoxetine; Humans; Meta-Analysis as Topic; Obsessive-Compulsive Disorder; Psychiatric | 1990 |
A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory.
Topics: 1-Naphthylamine; Adult; Ambulatory Care; Clinical Trials as Topic; Clomipramine; Double-Blind Method | 1990 |
Buspirone augmentation of fluoxetine in obsessive-compulsive disorder.
Topics: Adult; Buspirone; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluoxetine; Humans; M | 1990 |
Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results.
Topics: Adult; Blood Platelets; Clomipramine; Double-Blind Method; Female; Fluoxetine; Humans; Male; Obsessi | 1990 |
Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination.
Topics: Adolescent; Clomipramine; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Obsessive-Com | 1990 |
Long-term fluoxetine treatment of a large number of obsessive-compulsive patients.
Topics: Adult; Clinical Trials as Topic; Female; Fluoxetine; Humans; Long-Term Care; Male; Middle Aged; Obse | 1989 |
Fluoxetine treatment of obsessive-compulsive disorder: an open clinical trial.
Topics: Adult; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Fluoxetine; Follow-Up Stu | 1989 |
Fluoxetine treatment of obsessions and compulsions in patients with Tourette's syndrome.
Topics: Adult; Clinical Trials as Topic; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Propylamin | 1988 |
More on self mutilation and obsessive compulsive disorder.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Fluoxetine; Humans; Male; Obsessive-Compulsive | 1988 |
An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder.
Topics: Adult; Clinical Trials as Topic; Female; Fluoxetine; Humans; Male; Middle Aged; Obsessive-Compulsive | 1986 |
Fluoxetine treatment of obsessive-compulsive disorder.
Topics: Adult; Clinical Trials as Topic; Female; Fluoxetine; Humans; Male; Obsessive Behavior; Obsessive-Com | 1985 |
267 other studies available for fluoxetine and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder.
Topics: 3T3 Cells; Animals; Ethylamines; Female; Humans; Ligands; Male; Mice; Obsessive-Compulsive Disorder; | 1997 |
Fluoxetine-Induced Serum Sickness-Like Reaction in an Adolescent with Obsessive Compulsive Disorder and Diabetes.
Topics: Adolescent; Diabetes Mellitus; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Selective Serotoni | 2021 |
Distinct Patterns of Abnormal Lateral Orbitofrontal Cortex Activity During Compulsive Grooming and Reversal Learning Normalize After Fluoxetine.
Topics: Animals; Fluoxetine; Grooming; Mice; Mice, Knockout; Nerve Tissue Proteins; Obsessive-Compulsive Dis | 2023 |
Fluoxetine for the treatment of onychotillomania associated with obsessive-compulsive disorder: a case report.
Topics: Adolescent; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Paroxetine; Pharmaceutical Pr | 2022 |
Fluoxetine for the treatment of onychotillomania associated with obsessive-compulsive disorder: a case report.
Topics: Adolescent; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Paroxetine; Pharmaceutical Pr | 2022 |
Fluoxetine for the treatment of onychotillomania associated with obsessive-compulsive disorder: a case report.
Topics: Adolescent; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Paroxetine; Pharmaceutical Pr | 2022 |
Fluoxetine for the treatment of onychotillomania associated with obsessive-compulsive disorder: a case report.
Topics: Adolescent; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Paroxetine; Pharmaceutical Pr | 2022 |
Fluoxetine for the treatment of onychotillomania associated with obsessive-compulsive disorder: a case report.
Topics: Adolescent; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Paroxetine; Pharmaceutical Pr | 2022 |
Fluoxetine for the treatment of onychotillomania associated with obsessive-compulsive disorder: a case report.
Topics: Adolescent; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Paroxetine; Pharmaceutical Pr | 2022 |
Fluoxetine for the treatment of onychotillomania associated with obsessive-compulsive disorder: a case report.
Topics: Adolescent; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Paroxetine; Pharmaceutical Pr | 2022 |
Fluoxetine for the treatment of onychotillomania associated with obsessive-compulsive disorder: a case report.
Topics: Adolescent; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Paroxetine; Pharmaceutical Pr | 2022 |
Fluoxetine for the treatment of onychotillomania associated with obsessive-compulsive disorder: a case report.
Topics: Adolescent; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Paroxetine; Pharmaceutical Pr | 2022 |
Btbd3 expression regulates compulsive-like and exploratory behaviors in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Compulsive Behavior; Desipramine; Disease M | 2019 |
Obsessive-Compulsive Behaviors in Autism.
Topics: Adolescent; Autism Spectrum Disorder; Autistic Disorder; Child; Compulsive Behavior; Fluoxetine; Hum | 2020 |
The Effect of Lactobacillus casei Consumption in Improvement of Obsessive-Compulsive Disorder: an Animal Study.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Brain-Derived Neurotrophic Fact | 2020 |
Pica: obsessive-compulsive spectrum disorder, recurrent depression or eating disorder?
Topics: Adult; Anemia, Iron-Deficiency; Depression; Feeding and Eating Disorders; Female; Fluoxetine; Humans | 2020 |
Cell cycle abnormality is a cellular phenotype in OCD.
Topics: Cell Division; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Phenotype; Selective Serotonin Reu | 2021 |
Magic Shotgun Nature with Scattergun Approach of Curcumin Repurposing in Obsessive-compulsive Disorder: A Novel Metaphysician of Drug Discovery.
Topics: Animals; Behavior, Animal; Curcumin; Disease Models, Animal; Drug Discovery; Drug Repositioning; Flu | 2021 |
Obsessive-compulsive disorder presenting with gender incongruence obsessions.
Topics: Adult; Antipsychotic Agents; Fluoxetine; Gender Identity; Humans; Male; Obsessive-Compulsive Disorde | 2017 |
Postpartum Lactation-Mediated Behavioral Outcomes and Drug Responses in a Spontaneous Mouse Model of Obsessive-Compulsive Disorder.
Topics: Animals; Anxiety; Disease Models, Animal; Female; Fluoxetine; Lactation; Lactation Disorders; Mental | 2017 |
Obsession of pregnancy: Does it exist?
Topics: Attitude to Health; Citalopram; Clomipramine; Clonazepam; Cognitive Behavioral Therapy; Depressive D | 2017 |
Case report: Cytochrome P450 implications for comorbid ADHD and OCD pharmacotherapy.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Atomoxetine Hydrochloride; A | 2017 |
Therapeutic challenges in comorbid obsessive compulsive disorder with substance use.
Topics: Adrenergic alpha-2 Receptor Agonists; Clonazepam; Clonidine; Combined Modality Therapy; Fluoxetine; | 2018 |
Improved serotonergic neurotransmission by genistein pretreatment regulates symptoms of obsessive-compulsive disorder in streptozotocin-induced diabetic mice.
Topics: Animals; Behavior, Animal; Brain; Diabetes Mellitus, Experimental; Disease Models, Animal; Fluoxetin | 2018 |
Eighteen-year-old man with autism, obsessive compulsive disorder and a
Topics: Adolescent; Anorexia; Autistic Disorder; Fluoxetine; Humans; Male; Nerve Tissue Proteins; Obsessive- | 2018 |
The Stuck Song Syndrome: A Case of Musical Obsessions.
Topics: Adult; Chronic Disease; Female; Fluoxetine; Follow-Up Studies; Humans; Music; Obsessive-Compulsive D | 2018 |
Auto-Reactive Th17-Cells Trigger Obsessive-Compulsive-Disorder Like Behavior in Mice With Experimental Autoimmune Encephalomyelitis.
Topics: Adoptive Transfer; Animals; Autoimmunity; Behavior, Animal; Disease Models, Animal; Encephalomyeliti | 2018 |
Celecoxib potentiates the antianxiety and anticompulsive-like activity of fluoxetine against chronic unpredictable mild stress in experimental animals.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Celecoxib; Compulsive Behavior; Disease Mod | 2019 |
Oxcarbazepine and fluoxetine protect against mouse models of obsessive compulsive disorder through modulation of cortical serotonin and CREB pathway.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Carbamazepine; Cerebral Cortex; Cyclic AMP Respons | 2013 |
Repeated cortico-striatal stimulation generates persistent OCD-like behavior.
Topics: Adenoviridae; Animals; Artificial Gene Fusion; Bacterial Proteins; Behavior, Animal; Channelrhodopsi | 2013 |
Obsessive-compulsive-like behaviors in house mice are attenuated by a probiotic (Lactobacillus rhamnosus GG).
Topics: Animals; Antidepressive Agents, Second-Generation; Dietary Supplements; Disease Models, Animal; Expl | 2014 |
"The ickiness factor:" case study of an unconventional psychotherapeutic approach to pediatric OCD.
Topics: Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Defense Mechanisms; Depressive Disor | 2014 |
Animal behavior case of the month. Tail chasing in a dog diagnosed as compulsive disorder.
Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Bites and Stings; Cyclohexanecarboxylic Acids; D | 2015 |
Successful treatment of tuberous sclerosis with psychosis and obsessive-compulsive disorder: A case report.
Topics: Adult; Antipsychotic Agents; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Psychotic Diso | 2015 |
Association between the efficacy of fluoxetine treatment in obsessive-compulsive disorder patients and SLC1A1 in a Han Chinese population.
Topics: Adult; Asian People; Case-Control Studies; Excitatory Amino Acid Transporter 3; Female; Fluoxetine; | 2015 |
Memantine Augmentation in a Down's Syndrome Adolescent with Treatment- Resistant Obsessive-Compulsive Disorder.
Topics: Adolescent; Down Syndrome; Drug Synergism; Excitatory Amino Acid Antagonists; Fluoxetine; Humans; Ma | 2015 |
Clinically effective OCD treatment prevents 5-HT1B receptor-induced repetitive behavior and striatal activation.
Topics: Animals; Corpus Striatum; Desipramine; Exploratory Behavior; Female; Fluoxetine; Indoles; Mice; Mice | 2016 |
Urinary Retention in an Adolescent Patient Caused by Fluoxetine Alone.
Topics: Adolescent; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Selective Serotonin Reuptake | 2015 |
Recurrent brief depressive disorder in Dhat syndrome: A biological or psychological phenomenon!
Topics: Adult; Clomipramine; Cognitive Behavioral Therapy; Depressive Disorder; Fluoxetine; Humans; Male; Ob | 2016 |
Does dose-response relationship further support the concept of posttraumatic OCD.
Topics: Accidents, Traffic; Adult; Bipolar Disorder; Combat Disorders; Dose-Response Relationship, Drug; Flu | 2016 |
Staying Up at Night: Overlapping Bipolar and Obsessive-Compulsive Disorder Symptoms in an Adolescent with Autism Spectrum Disorder.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Autism Spectrum Disorder | 2016 |
Fluoxetine Adjunctive Therapy for Obsessive-Compulsive Symptoms Associated With Olanzapine in Schizophrenic Patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Fluoxetine; Humans; | 2016 |
Behavioral and pharmacological phenotypes of brain-specific diacylglycerol kinase δ-knockout mice.
Topics: Animals; Behavior, Animal; Brain; Cell Line, Tumor; Diacylglycerol Kinase; Female; Fluoxetine; Isoen | 2016 |
Effectiveness of add-on l-methylfolate therapy in a complex psychiatric illness with MTHFR C677 T genetic polymorphism.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disor | 2016 |
Pediatric Obsessive-Compulsive Disorder Exacerbation and Obstructive Hydrocephalus: A Case Report.
Topics: Brain Neoplasms; Child; Fluoxetine; Glioma; Humans; Hydrocephalus; Male; Obsessive-Compulsive Disord | 2016 |
Diagnosis and treatment of obsessive compulsive behavior in a boy with Duchenne muscular dystrophy and autism spectrum disorder: A case report.
Topics: Autism Spectrum Disorder; Child; Comorbidity; Fluoxetine; Humans; Male; Muscular Dystrophy, Duchenne | 2016 |
Animal Behavior Case of the Month.
Topics: Animals; Behavior, Animal; Diagnosis, Differential; Dog Diseases; Dogs; Fluoxetine; Male; Obsessive- | 2016 |
Pharmacogenetic study focused on fluoxetine pharmacodynamics in children and adolescent patients: impact of the serotonin pathway.
Topics: Adolescent; Anxiety Disorders; Child; Depressive Disorder; Female; Fluoxetine; Humans; Male; Mental | 2016 |
OCD-like behavior is caused by dysfunction of thalamo-amygdala circuits and upregulated TrkB/ERK-MAPK signaling as a result of SPRED2 deficiency.
Topics: Amygdala; Animals; Compulsive Behavior; Corpus Striatum; Extracellular Signal-Regulated MAP Kinases; | 2018 |
An adolescent male with features of EDNOS and obsessive-compulsive disorder.
Topics: Adolescent; Body Mass Index; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; D | 2008 |
Dopaminergic and serotonergic modulation of persistent behaviour in the reinforced spatial alternation model of obsessive-compulsive disorder.
Topics: Animals; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Fluoxetine; Ma | 2008 |
Treatment-resistant self-mutilation, tics, and obsessive-compulsive disorder in neuroacanthocytosis: a mouth guard as a therapeutic approach.
Topics: Adult; Antipsychotic Agents; Atrophy; Caudate Nucleus; Clonazepam; Clozapine; Dibenzothiazepines; El | 2008 |
Effectiveness of fluoxetine on various subtypes of obsessive-compulsive disorder.
Topics: Female; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Selective Serotonin Reuptake Inhibi | 2008 |
Is Pica an eating disorder or an obsessive-compulsive spectrum disorder?
Topics: Antidepressive Agents, Second-Generation; Child; Feeding and Eating Disorders; Fluoxetine; Humans; M | 2008 |
Prolonged neonatal complications after in utero exposure to fluoxetine.
Topics: Adult; Diagnosis, Differential; Female; Fluoxetine; Humans; Infant, Newborn; Neonatal Abstinence Syn | 2008 |
Recent NIMH clinical trials and implications for practice.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System | 2008 |
Efficacy and safety of fluoxetine in preschool children with obsessive-compulsive disorder.
Topics: Antipsychotic Agents; Child, Preschool; Dose-Response Relationship, Drug; Female; Fluoxetine; Humans | 2009 |
Neurosteroids modulate compulsive and persistent behavior in rodents: implications for obsessive-compulsive disorder.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Behavior, Animal; Dehydroepia | 2009 |
Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.
Topics: Adult; Clomipramine; Connecticut; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Obsess | 2010 |
The combined effects of memantine and fluoxetine on an animal model of obsessive compulsive disorder.
Topics: Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Fluoxetine; Male; Memant | 2009 |
MRI study of the cavum septum pellucidum in obsessive-compulsive disorder.
Topics: Adult; Case-Control Studies; Chi-Square Distribution; Female; Fluoxetine; Humans; Image Processing, | 2010 |
The drug-naïve OCD patients imaging genetics, cognitive and treatment response study: methods and sample description.
Topics: Adolescent; Adult; Aged; Cognitive Behavioral Therapy; Fluoxetine; Humans; Magnetic Resonance Imagin | 2009 |
Sertraline-induced enuresis in a prepubertal child resolves after switching to fluoxetine.
Topics: Child; Enuresis; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Selective Serotonin Reupta | 2010 |
Knocking out compulsive behavior.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Fluoxetine; Frontal Lobe; Humans | 2010 |
[Fluoxetine-induced tics in a child].
Topics: Child; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Selective Serotonin Reuptake Inhib | 2011 |
The involvement of distinct neural systems in patients with obsessive-compulsive disorder with autogenous and reactive obsessions.
Topics: Adult; Aspartic Acid; Choline; Creatine; Diagnostic and Statistical Manual of Mental Disorders; Drug | 2011 |
Raynaud’s phenomenon in a patient with schizophrenia and obsessive-compulsive disorder: a case report.
Topics: Amlodipine; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Clonaze | 2011 |
Treatment practices in Tourette syndrome: the European perspective.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Atomoxetine Hydrochloride | 2012 |
Preschool children with obsessive-compulsive disorder and fluoxetine treatment.
Topics: Child, Preschool; Diagnostic and Statistical Manual of Mental Disorders; Female; Fluoxetine; Humans; | 2012 |
Role of 5-hydroxytryptamine2C receptors in marble-burying behavior in mice.
Topics: Aminopyridines; Amphetamines; Animals; Behavior, Animal; Fluoxetine; Indoles; Male; Mice; Mice, Inbr | 2012 |
Increased serotonergic neurotransmission is not responsible for the anticompulsive effect of berberine in a murine model of obsessive-compulsive disorder.
Topics: Aniline Compounds; Animals; Behavior, Animal; Berberine; Disease Models, Animal; Dose-Response Relat | 2012 |
Late occurrence of isolated obsessive-compulsive behavior in a boy with Wilson's Disease on treatment.
Topics: Antidepressive Agents, Second-Generation; Child; Disease Progression; Fluoxetine; Hepatolenticular D | 2013 |
Serotonin reuptake inhibitor treatment of obsessive-compulsive symptoms in clozapine-medicated schizophrenia.
Topics: Adult; Antipsychotic Agents; Aryl Hydrocarbon Hydroxylases; Clomipramine; Clozapine; Comorbidity; Cy | 2012 |
Naltrexone treatment of kleptomania: a case report.
Topics: Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depressive Disorder; Diagnos | 2012 |
Effects of chronic fluoxetine treatment on serotonin 1B receptor-induced deficits in delayed alternation.
Topics: Animals; Dose-Response Relationship, Drug; Female; Fluoxetine; Frontal Lobe; Maze Learning; Memory, | 2013 |
Sex- and endocrine-stage-differences in middle-aged rats in an animal model of OCD.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Age Factors; Analysis of Variance; Animals; Disease Models, | 2013 |
Addition of cognitive-behaviour therapy for obsessive-compulsive disorder patients non-responding to fluoxetine.
Topics: Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Fluoxetine; Humans; Male; Ob | 2002 |
Effect of YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT 2A receptor antagonistic activity, on a marble-burying behavior test as an obsessive-compulsive disorder model.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Disease Models, Animal; Dose-Response | 2002 |
Clomipramine-resistant, fluoxetine-responsive obsessive compulsive disorder: a case report.
Topics: Adult; Clomipramine; Drug Resistance; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Selec | 2002 |
[Compulsive-obsessive disorder after severe head trauma: diagnosis and treatment].
Topics: Adult; Brain Injury, Chronic; Diagnostic Imaging; Fluoxetine; Follow-Up Studies; Frontal Lobe; Human | 2003 |
Reply to Dr Mahendran. We have not found reported cases of [obsessive-compulsive] OC arising from de novo with olanzapine treatment.
Topics: Adult; Benzodiazepines; Clomipramine; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Olanz | 2003 |
Fluoxetine in Alzheimer's disease with severe obsessive compulsive symptoms and a low density of serotonin transporter sites.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Binding Sites; Brain; Carrier Proteins; Female; Fluoxeti | 2003 |
Obsessive-compulsive symptoms in schizophrenia induced by risperidone and responding to fluoxetine.
Topics: Antipsychotic Agents; Chronic Disease; Fluoxetine; Humans; Male; Middle Aged; Obsessive-Compulsive D | 2003 |
Long-term treatment of an addictive personality.
Topics: Adult; Antidepressive Agents, Second-Generation; Behavior, Addictive; Depressive Disorder; Diagnosis | 2003 |
Patients with obsessive-compulsive disorder (OCD) displayed cognitive deficits consistent with a dysfunction of the dorsolateral-striatal circuit.
Topics: Analysis of Variance; Antidepressive Agents, Second-Generation; Cognition; Fluoxetine; Humans; Neuro | 2004 |
Obsessive-compulsive disorder in patients with velocardiofacial (22q11 deletion) syndrome.
Topics: Adolescent; Adult; Child; Chromosomes, Human, Pair 22; Craniofacial Abnormalities; Female; Fluoxetin | 2004 |
Antidepressant medications in children.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Causality; Child; Depressive Disorder; Fluoxet | 2004 |
Treatment outcome of schizophrenia co-morbid with obsessive-compulsive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Comorbidity; Fluoxetine; Huma | 2004 |
Fluvoxamine: new indication. No progress in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Child; Drug Approval; Fluoxetine; France; Humans; Obsessive-Compulsive Disorder; | 2004 |
Case study: successful medication withdrawal using cognitive-behavioral therapy for a preadolescent with OCD.
Topics: Child; Clomipramine; Cognitive Behavioral Therapy; Female; Fluoxetine; Humans; Obsessive-Compulsive | 2004 |
Comment on adult baby syndrome.
Topics: Adult; Antipsychotic Agents; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Paraphilic Dis | 2004 |
Patients with obsessive-compulsive disorder (OCD) displayed cognitive deficits consistent with a dysfunction of the dorsolateral-striatal circuit.
Topics: Cognition Disorders; Corpus Striatum; Fluoxetine; Fluvoxamine; Frontal Lobe; Humans; Nerve Net; Neur | 2004 |
Reinforced spatial alternation as an animal model of obsessive-compulsive disorder (OCD): investigation of 5-HT2C and 5-HT1D receptor involvement in OCD pathophysiology.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Desipramine; Diazepam; Disease Model | 2005 |
Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying.
Topics: Animals; Anxiety; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoxetine; Habituation, | 2006 |
Cognitive behavioral therapy versus psychosurgery for refractory obsessive-compulsive disorder.
Topics: Clomipramine; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Fluoxetine; Fluvoxami | 2006 |
Oral contraceptive pill use and changes in obsessive-compulsive symptoms.
Topics: Adult; Clomipramine; Contraceptives, Oral, Hormonal; Drug Therapy, Combination; Female; Fluoxetine; | 2006 |
Severe stuttering and motor tics responsive to cocaine.
Topics: Adult; Cocaine; Dopamine Agonists; Fluoxetine; Humans; Levodopa; Male; Obsessive-Compulsive Disorder | 2007 |
Ovarian steroids counteract serotonergic drugs actions in an animal model of obsessive-compulsive disorder.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Estradiol; Estrous Cycle; Female; Fluoxetine; Obses | 2006 |
A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Behavior, Animal; Diazepa | 2006 |
Symptom remission in OCD after discontinuation of pharmacotherapy with fluoxetine: a case for looking beyond serotonin.
Topics: Adult; Drug Administration Schedule; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Remiss | 2007 |
Trichotillomania and co-morbid psychiatric disorders in a 10-year-old boy.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Comorbidity; Drug Therapy, Combinat | 2007 |
LHRH antagonist attenuates the effect of fluoxetine on marble-burying behavior in mice.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, C | 2007 |
Tics, anxiety, and possible PANDAS in an adolescent.
Topics: Adolescent; Adrenergic alpha-Agonists; Antidepressive Agents, Second-Generation; Anxiety; Autoimmune | 2007 |
Stereotypic behaviour in the deer mouse: pharmacological validation and relevance for obsessive compulsive disorder.
Topics: Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Desipramine; Disease Models, Animal; Do | 2008 |
Should young people be given antidepressants? No.
Topics: Antidepressive Agents; Child; Depressive Disorder; Fluoxetine; Humans; Obsessive-Compulsive Disorder | 2007 |
Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
Topics: Adult; Citalopram; Clomipramine; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexan | 2007 |
Sertraline and tic: case report.
Topics: Adult; Depressive Disorder, Major; Eyelids; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorde | 2007 |
Cognitive versus behavior therapy: processes of change in the treatment of obsessive-compulsive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Behavior Therapy; Cognitive Behav | 2008 |
Risperidone treatment for a Tourette's disorder patient with comorbid obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Comorbidity; Depressive Disorder; Drug Therapy, Combination; Fluoxetine | 1995 |
Cats as possible obsessive-compulsive disorder and medication models.
Topics: Animals; Cat Diseases; Cats; Disease Models, Animal; Female; Fluoxetine; Humans; Obsessive-Compulsiv | 1995 |
[Personality disorders and obsessive-compulsive disorder: critical analysis of the literature data and our studies].
Topics: Clomipramine; Comorbidity; Depressive Disorder; Fluoxetine; Humans; Obsessive-Compulsive Disorder; P | 1995 |
Changes in paroxetine binding in the cerebral cortex of polydipsic rats.
Topics: Animals; Binding, Competitive; Cerebral Cortex; Disease Models, Animal; Drinking Behavior; Fluoxetin | 1995 |
Fluoxetine-clomipramine interaction.
Topics: Adult; Clomipramine; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Fem | 1995 |
Re: Bradycardia and somnolence after adding fluoxetine to pimozide regimen.
Topics: Aged; Bradycardia; Brain Stem; Cerebral Cortex; Dementia; Dominance, Cerebral; Drug Synergism; Fluox | 1994 |
Similarities in response to fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder.
Topics: Adolescent; Adolescent Behavior; Antidepressive Agents, Tricyclic; Child; Child Behavior Disorders; | 1995 |
Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder.
Topics: Animals; Clomipramine; Conditioning, Operant; Desipramine; Diazepam; Disease Models, Animal; Drinkin | 1993 |
Exacerbation of obsessive-compulsive symptoms associated with clozapine.
Topics: Adult; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Comb | 1994 |
Discontinuing obsessive-compulsive disorder medication with behavior therapy.
Topics: Adult; Behavior Therapy; Clomipramine; Combined Modality Therapy; Female; Fluoxetine; Follow-Up Stud | 1994 |
Sexual obsessions associated with fluoxetine.
Topics: Depressive Disorder; Dreams; Female; Fluoxetine; Humans; Libido; Middle Aged; Obsessive-Compulsive D | 1994 |
Valproate pretreatment for the difficult-to-treat patient with OCD.
Topics: 1-Naphthylamine; Antidepressive Agents; Clomipramine; Drug Therapy, Combination; Fluoxetine; Humans; | 1994 |
Treatment of obsessive-compulsive symptoms in schizophrenia with a neuroleptic-selective serotonin reuptake inhibitor combination: two case reports.
Topics: Adult; Aged; Antipsychotic Agents; Clomipramine; Drug Therapy, Combination; Fluoxetine; Humans; Male | 1994 |
Fluoxetine and memory impairment.
Topics: Adult; Amnesia; Cerebral Cortex; Dominance, Cerebral; Dopamine Antagonists; Feeding and Eating Disor | 1994 |
Fluvoxamine in obsessive-compulsive nonresponders to clomipramine or fluoxetine.
Topics: Adult; Clomipramine; Fluoxetine; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Severity of Ill | 1994 |
Treatment of schizophrenia with obsessive-compulsive features with serotonin reuptake inhibitors.
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Fluoxetine; Humans; Male; Obsessive-Compulsi | 1993 |
Pharmacologic management of obsessive-compulsive disorder.
Topics: 1-Naphthylamine; Antidepressive Agents; Anxiety Disorders; Clomipramine; Depression; Dopamine; Fluox | 1994 |
Familial obsessive-compulsive disorder presenting as pathological jealousy successfully treated with fluoxetine.
Topics: Adult; Drug Administration Schedule; Family; Female; Fluoxetine; Humans; Jealousy; Obsessive-Compuls | 1994 |
Fluoxetine in Tourette's syndrome.
Topics: Acute Disease; Adult; Fluoxetine; Humans; Male; Nail Biting; Obsessive-Compulsive Disorder; Severity | 1994 |
Association of fluoxetine and return of sexual potency in three elderly men.
Topics: Age Factors; Aged; Comorbidity; Depressive Disorder; Erectile Dysfunction; Fluoxetine; Humans; Libid | 1993 |
Fluoxetine for obsessional symptoms in schizophrenia.
Topics: Adult; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Schizophrenia; Schizophrenic Psych | 1994 |
Fluoxetine in obsessive compulsive disorder in adolescents.
Topics: Adolescent; Child; Comorbidity; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administ | 1993 |
Individual differences in cerebral metabolic patterns during pharmacotherapy in obsessive-compulsive disorder: a multiple regression/discriminant analysis of positron emission tomographic data.
Topics: Adult; Brain; Clomipramine; Discriminant Analysis; Female; Fluoxetine; Humans; Male; Middle Aged; Ob | 1993 |
Serotonin reuptake blockers for the treatment of obsessional jealousy.
Topics: 1-Naphthylamine; Adult; Clomipramine; Drug Therapy, Combination; Female; Fluoxetine; Humans; Jealous | 1994 |
Prescribing attitudes of different physician groups regarding fluoxetine.
Topics: Depressive Disorder; Drug Utilization; Female; Florida; Fluoxetine; Health Knowledge, Attitudes, Pra | 1993 |
Clozapine, obsessive symptoms, and serotonergic mechanisms.
Topics: Clozapine; Drug Therapy, Combination; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Schizophren | 1993 |
Clozapine, obsessive symptoms, and serotonergic mechanisms.
Topics: Clozapine; Drug Therapy, Combination; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Receptors, | 1993 |
Drug-induced mania.
Topics: Bipolar Disorder; Clomipramine; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; O | 1993 |
Fluoxetine and memory impairment.
Topics: Adult; Amnesia; Dose-Response Relationship, Drug; Feeding and Eating Disorders; Female; Fluoxetine; | 1993 |
Tourette's syndrome and nicotine withdrawal.
Topics: Adult; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Smoking Cessation; Tourette Syndro | 1993 |
Managing psychotic symptoms when the diagnosis is unclear.
Topics: Adult; Diagnosis, Differential; Fluoxetine; Fluphenazine; Humans; Male; Obsessive-Compulsive Disorde | 1993 |
Obsessive-compulsive disorder, fluoxetine, and buspirone.
Topics: Buspirone; Drug Administration Schedule; Drug Therapy, Combination; Fluoxetine; Humans; Male; Middle | 1993 |
Possible interaction between fluoxetine and pimozide causing sinus bradycardia.
Topics: Aged; Arrhythmia, Sinus; Bradycardia; Delusions; Dementia; Depressive Disorder; Dose-Response Relati | 1993 |
Development of obsessive-compulsive symptoms during clozapine treatment.
Topics: Adult; Clozapine; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Schizophrenia | 1993 |
Postpartum obsessive compulsive disorder: a case series.
Topics: Adult; Clomipramine; Desipramine; Diagnosis, Differential; Female; Fluoxetine; Follow-Up Studies; Hu | 1993 |
The benefits of clomipramine-fluoxetine combination in obsessive compulsive disorder.
Topics: Adult; Clomipramine; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combinatio | 1993 |
Obsessive-compulsive disorder, trichotillomania, and anorexia nervosa: a case report.
Topics: Adolescent; Anorexia Nervosa; Combined Modality Therapy; Female; Fluoxetine; Humans; Obsessive-Compu | 1995 |
Tardive dyskinesia associated with fluoxetine.
Topics: Adult; Clomipramine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Fluoxetine; Humans; Male; | 1996 |
Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Relevance to treatment of obsessive-compulsive disorder.
Topics: Animals; Dose-Response Relationship, Drug; Fluoxetine; Frontal Lobe; Guinea Pigs; Male; Obsessive-Co | 1995 |
Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.
Topics: Alcohol Withdrawal Delirium; Buspirone; Clomipramine; Diagnosis, Differential; Drug Therapy, Combina | 1996 |
Effects of third trimester fluoxetine exposure on the newborn.
Topics: Abnormalities, Drug-Induced; Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; D | 1995 |
Naltrexone for the treatment of trichotillomania: a case report.
Topics: Drug Synergism; Drug Therapy, Combination; Female; Fluoxetine; Humans; Middle Aged; Naltrexone; Narc | 1995 |
Will pindolol augment the response to a serotonin reuptake inhibitor in obsessive-compulsive disorder?
Topics: 1-Naphthylamine; Adrenergic beta-Antagonists; Adult; Antidepressive Agents; Clomipramine; Drug Syner | 1996 |
AIDS-related obsessive compulsive disorder: deconditioning based on fluoxetine-induced inhibition of anxiety.
Topics: Acquired Immunodeficiency Syndrome; Adult; Combined Modality Therapy; Desensitization, Psychologic; | 1996 |
Effects of serotonergic agents on food-restriction-induced hyperactivity.
Topics: Animals; Antidepressive Agents, Tricyclic; Body Weight; Disease Models, Animal; Eating; Female; Fenc | 1996 |
Maternal obsessions of child sexual abuse.
Topics: Adult; Child; Child Abuse, Sexual; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressi | 1996 |
Antidepressant induced mania in obsessive compulsive disorder.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Citalopram; Clomipramine; Female; Fluoxetine; Follow | 1996 |
Potentiation of fluoxetine by aminoglutethimide, an adrenal steroid suppressant, in obsessive-compulsive disorder resistant to SSRIs: a case report.
Topics: Aminoglutethimide; Drug Interactions; Fluoxetine; Humans; Male; Middle Aged; Obsessive-Compulsive Di | 1996 |
Body dysmorphic disorder.
Topics: Body Image; Child; Child Behavior Disorders; Comorbidity; Dose-Response Relationship, Drug; Drug Adm | 1996 |
Inability to cry during SRI treatment.
Topics: 1-Naphthylamine; Adult; Crying; Depressive Disorder; Emotions; Female; Fluoxetine; Humans; Obsessive | 1996 |
Ritanserin as adjunct to fluoxetine treatment of OCD patients with psychotic features.
Topics: Adult; Antidepressive Agents, Second-Generation; Drug Therapy, Combination; Female; Fluoxetine; Huma | 1997 |
Juvenile obsessive-compulsive disorder.
Topics: Adolescent; Child; Clomipramine; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidit | 1997 |
Use of fluoxetine for obsessive-compulsive behavior in adults with autism.
Topics: Adult; Autistic Disorder; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder | 1997 |
A case of pica--neither a compulsion nor an impulse.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Diagnosis, Differential; Fluoxetine; Humans; I | 1996 |
Potential fluoxetine chloride (Prozac) toxicity in a newborn.
Topics: Adult; Antidepressive Agents, Second-Generation; Female; Fetus; Fluoxetine; Follow-Up Studies; Human | 1997 |
Behavioral therapy in children and adolescents with obsessive-compulsive disorder: a pilot study.
Topics: 1-Naphthylamine; Adolescent; Behavior Therapy; Child; Combined Modality Therapy; Female; Fluoxetine; | 1996 |
Psychopharmacology of comorbid obsessive-compulsive disorder and depression.
Topics: Comorbidity; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Se | 1997 |
Serotonin syndrome presenting with migrainelike stroke.
Topics: Adult; Brain Ischemia; Cerebrovascular Circulation; Cerebrovascular Disorders; Clomipramine; Confusi | 1997 |
Ninety-three--and washing.
Topics: Aged; Aged, 80 and over; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Selective Seroto | 1997 |
Olfactory reference syndrome responds to clomipramine but not fluoxetine: a case report.
Topics: Adult; Clomipramine; Comorbidity; Delusions; Depressive Disorder; Fluoxetine; Humans; Male; Obsessiv | 1997 |
Rebound psychiatric and physical symptoms after gabapentin discontinuation.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Fluoxetin | 1998 |
Aplastic anaemia during treatment with fluoxetine.
Topics: Adult; Anemia, Aplastic; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Selective Serotoni | 1998 |
Risperidone may worsen fluoxetine-treated OCD.
Topics: Acute Disease; Adult; Antipsychotic Agents; Drug Administration Schedule; Drug Interactions; Drug Th | 1998 |
Obsessive-compulsive disorder in post-streptococcal infection.
Topics: Adult; Antidepressive Agents, Second-Generation; Attitude to Health; Female; Fluoxetine; Humans; Hyg | 1998 |
Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Fluoxetine; Humans; | 1998 |
An adolescent male with multiple paraphilias successfully treated with fluoxetine.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Bipolar Disorder; Fluoxetine; Humans; Male; Ob | 1998 |
Fluoxetine versus phenelzine in obsessive-compulsive disorder.
Topics: Antidepressive Agents; Controlled Clinical Trials as Topic; Drug Administration Schedule; Fluoxetine | 1999 |
Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive-compulsive disorder.
Topics: Animals; Antidepressive Agents; Benzamides; Brain; Electroconvulsive Therapy; Fluoxetine; Guinea Pig | 1999 |
Rapid remission of OCD with tramadol hydrochloride.
Topics: Adult; Analgesics, Opioid; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxeti | 1999 |
Obsessive-compulsive symptoms with risperidone.
Topics: Antipsychotic Agents; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Fluox | 1999 |
Olanzapine-induced obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clomipramine; Fluoxetine; Humans; Male; Obsessive-Comp | 1999 |
Treatment of obsessive-compulsive disorder using clomipramine in a very old patient.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; B | 1999 |
Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Clomipramine; Comorbidity; Controlled Clinical Trials as T | 1999 |
A child with severe head banging.
Topics: Autistic Disorder; Child; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Selective Seroton | 1999 |
Obsessive-compulsive disorder: evaluation of clinical and biological circadian parameters during fluoxetine treatment.
Topics: Adult; Body Temperature; Circadian Rhythm; Female; Fluoxetine; Humans; Hydrocortisone; Male; Melaton | 1999 |
Possible interaction of tramadol and antidepressants.
Topics: Antidepressive Agents; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Obs | 2000 |
Fluoxetine in the treatment of self-mutilating behavior.
Topics: Adolescent; Child; Child, Preschool; Disruptive, Impulse Control, and Conduct Disorders; Fluoxetine; | 2000 |
Fluoxetine in the treatment of Huntington's disease.
Topics: Affect; Aggression; Antidepressive Agents, Second-Generation; Cognition Disorders; Disease Progressi | 2001 |
Antidepressant augmentation with low-dose olanzapine in obsessive-compulsive disorder.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Interactions; Fluoxetine; Humans; Male; Middle Aged; Obs | 2000 |
Antibodies against human putamen in adolescents with anorexia nervosa.
Topics: Adolescent; Anorexia Nervosa; Antibodies; Benzodiazepines; Body Mass Index; Caudate Nucleus; Enzyme- | 2001 |
Excessive lever pressing following post-training signal attenuation in rats: a possible animal model of obsessive compulsive disorder?
Topics: Animals; Behavior, Animal; Conditioning, Operant; Cues; Diazepam; Disease Models, Animal; Fluoxetine | 2001 |
Amotivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents.
Topics: Adolescent; Anxiety Disorders; Child; Depressive Disorder; Female; Fluoxetine; Humans; Male; Motivat | 2001 |
In-patient treatment for resistant obsessive-compulsive disorder.
Topics: Adult; Clomipramine; Combined Modality Therapy; Desensitization, Psychologic; Female; Fluoxetine; Ho | 2000 |
Vasopressin-dependent flank marking in golden hamsters is suppressed by drugs used in the treatment of obsessive-compulsive disorder.
Topics: Adrenergic Uptake Inhibitors; Aggression; Animals; Arginine Vasopressin; Behavior, Animal; Clomipram | 2001 |
Extending indications for long-term pharmacotherapy: opportunities and challenges.
Topics: Bulimia; Chronic Disease; Fluoxetine; Humans; Long-Term Care; Obsessive-Compulsive Disorder; Sertral | 2002 |
Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders.
Topics: Adolescent; Adult; Age Factors; Autistic Disorder; Brain; Brain Chemistry; Child; Child Development | 2002 |
Fluoxetine for OCD after brain injury.
Topics: Adolescent; Brain Injuries; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Selective Serot | 2002 |
Fluoxetine-induced extrapyramidal symptoms in an adolescent: a case report.
Topics: Adolescent; Basal Ganglia Diseases; Conduct Disorder; Depression; Drug Hypersensitivity; Female; Flu | 2002 |
Serotonergic medications for sexual obsessions, sexual addictions, and paraphilias.
Topics: Adolescent; Adult; Behavior, Addictive; Clomipramine; Fenfluramine; Fluoxetine; Fluvoxamine; Humans; | 1992 |
[Pharmacotoxic psychosis and extrapyramidal motor syndrome. A case of acute adverse effect of fluoxetine and flupenthixol].
Topics: Adult; Basal Ganglia Diseases; Female; Fluoxetine; Flupenthixol; Humans; Neurologic Examination; Obs | 1992 |
Fluoxetine and depersonalization syndrome.
Topics: Bipolar Disorder; Depersonalization; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder | 1992 |
Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration.
Topics: Adult; Brain; Confidence Intervals; Depressive Disorder; Female; Fluorine; Fluoxetine; Humans; Magne | 1992 |
A fluvoxamine-induced frontal lobe syndrome in a patient with comorbid Gilles de la Tourette's syndrome and obsessive compulsive disorder.
Topics: Adult; Brain Diseases; Dopamine; Fluoxetine; Frontal Lobe; Humans; Male; Obsessive-Compulsive Disord | 1992 |
Adverse vascular effects associated with fluoxetine.
Topics: Adult; Depressive Disorder; Ecchymosis; Epistaxis; Fluoxetine; Hemorrhage; Humans; Male; Obsessive-C | 1992 |
Pharmacologic treatment of severe skin-picking behaviors in Prader-Willi syndrome. Two case reports.
Topics: Adult; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Prader-Willi Syndrome; Self | 1992 |
Treatment outcome of obsessive compulsive disorder with comorbid social phobia.
Topics: Adult; Clomipramine; Comorbidity; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Obsess | 1992 |
Buspirone and fluoxetine in the treatment of OCD.
Topics: Adult; Arousal; Buspirone; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Obsessive-Co | 1992 |
Adverse cutaneous reactions associated with fluoxetine strategy for reintroduction of this drug in selected patients.
Topics: Adult; Clinical Protocols; Depressive Disorder; Desensitization, Immunologic; Dose-Response Relation | 1992 |
Fluoxetine treatment of slow eating.
Topics: Adult; Feeding Behavior; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Panic Disorder | 1992 |
Antidepressant-induced mania in obsessive-compulsive disorder.
Topics: Bipolar Disorder; Clomipramine; Fluoxetine; Humans; Norepinephrine; Obsessive-Compulsive Disorder; S | 1992 |
Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder.
Topics: Adult; Behavior Therapy; Caudate Nucleus; Cerebral Cortex; Deoxyglucose; Female; Fluorodeoxyglucose | 1992 |
Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder.
Topics: Adult; Behavior Therapy; Caudate Nucleus; Cerebral Cortex; Deoxyglucose; Female; Fluorodeoxyglucose | 1992 |
Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder.
Topics: Adult; Behavior Therapy; Caudate Nucleus; Cerebral Cortex; Deoxyglucose; Female; Fluorodeoxyglucose | 1992 |
Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder.
Topics: Adult; Behavior Therapy; Caudate Nucleus; Cerebral Cortex; Deoxyglucose; Female; Fluorodeoxyglucose | 1992 |
Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy.
Topics: Adult; Age Factors; Brain; Caudate Nucleus; Cerebral Cortex; Clomipramine; Female; Fluoxetine; Follo | 1992 |
Seizure associated with fluoxetine and adjuvant buspirone therapy.
Topics: Adult; Buspirone; Drug Therapy, Combination; Epilepsy, Tonic-Clonic; Fluoxetine; Humans; Male; Obses | 1992 |
A case of fluoxetine-responsive psychogenic polydipsia: a variant of obsessive-compulsive disorder?
Topics: Adult; Compulsive Behavior; Diagnosis, Differential; Drinking; Drug Administration Schedule; Fluoxet | 1992 |
Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder.
Topics: Adult; Antidepressive Agents, Tricyclic; Arousal; Brain; Depressive Disorder; Dreams; Electroencepha | 1992 |
Fluoxetine and schizophrenia in a patient with obsessional thinking.
Topics: Adult; Drug Therapy, Combination; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Psychoses | 1992 |
Fluoxetine treatment of children and adults with autistic disorder and mental retardation.
Topics: Adolescent; Adult; Autistic Disorder; Child; Female; Fluoxetine; Humans; Intellectual Disability; Ma | 1992 |
Response of obsessive-compulsive disorder and trichotillomania to serotonin reuptake blockers.
Topics: Adolescent; Clomipramine; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Trichotillomani | 1992 |
Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation.
Topics: Fluoxetine; Humans; Obsessive-Compulsive Disorder; Time Factors | 1991 |
Hair loss associated with fluoxetine treatment.
Topics: Adult; Alopecia; Dose-Response Relationship, Drug; Female; Fluoxetine; Humans; Obsessive-Compulsive | 1991 |
Hypochondriasis and obsessive compulsive disorder: overlaps in diagnosis and treatment.
Topics: Adult; Aged; Comorbidity; Female; Fluoxetine; Humans; Hypochondriasis; Male; Middle Aged; Obsessive- | 1991 |
Paranoid and aggressive behavior in two obsessive-compulsive adolescents treated with clomipramine.
Topics: Adolescent; Aggression; Carbamazepine; Child; Clomipramine; Dose-Response Relationship, Drug; Fluoxe | 1991 |
Fluoxetine treatment of obsessive-compulsive disorder.
Topics: Adult; Arousal; Clomipramine; Combined Modality Therapy; Depressive Disorder; Drive; Female; Fluoxet | 1991 |
Spontaneous alternation behavior: an animal model for obsessive-compulsive disorder?
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Disease Models, Animal; Fluoxetin | 1991 |
Treatment of cancer phobia with fluoxetine.
Topics: Adult; Female; Fluoxetine; Humans; Hypochondriasis; Neoplasms; Obsessive-Compulsive Disorder | 1991 |
Effects of fluoxetine on regional cerebral blood flow in obsessive-compulsive patients.
Topics: Adult; Anxiety; Cerebral Cortex; Cerebrovascular Circulation; Female; Fluoxetine; Frontal Lobe; Huma | 1991 |
Appearance of obsessive-compulsive symptoms in depressed patients treated with fluoxetine.
Topics: Adult; Depressive Disorder; Female; Fluoxetine; Humans; Middle Aged; Obsessive-Compulsive Disorder | 1991 |
Fluoxetine and suicidal ideation.
Topics: Adolescent; Anxiety, Separation; Dose-Response Relationship, Drug; Fluoxetine; Humans; Male; Obsessi | 1991 |
Fluoxetine-induced mania in a patient with obsessive-compulsive disorder.
Topics: Adult; Bipolar Disorder; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder | 1991 |
Lithium augmentation of fluoxetine in the treatment of OCD and major depression: a case report.
Topics: Adult; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Flu | 1991 |
Three cases of pharmacotherapy of obsessive-compulsive disorder in the elderly.
Topics: Age Factors; Aged; Clomipramine; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Tr | 1991 |
Buspirone augmentation of fluoxetine in a depressed child with obsessive-compulsive disorder.
Topics: Buspirone; Child, Preschool; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Hum | 1991 |
Are effective antiobsessional drugs interchangeable?
Topics: Clomipramine; Fluoxetine; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Research Design; Serot | 1991 |
Treatment of psychotic symptoms in OCD patients.
Topics: Antipsychotic Agents; Catatonia; Drug Therapy, Combination; Female; Fluoxetine; Humans; Middle Aged; | 1990 |
Potential antidopaminergic effects of serotonin reuptake inhibitors.
Topics: Animals; Clomipramine; Dopamine Antagonists; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Rats | 1991 |
Severe hair loss associated with fluoxetine use.
Topics: Alopecia; Female; Fluoxetine; Humans; Middle Aged; Obsessive-Compulsive Disorder | 1991 |
Fluoxetine for obsessive fear of loss of control of malodorous flatulence.
Topics: Adult; Fear; Flatulence; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder | 1991 |
Fluoxetine and neuroleptic synergistic effects.
Topics: Adolescent; Chlorpromazine; Diseases in Twins; Drug Synergism; Fluoxetine; Haloperidol; Humans; Male | 1991 |
A fluoxetine-induced frontal lobe syndrome in an obsessive compulsive patient.
Topics: Adult; Brain Diseases; Cerebrovascular Circulation; Fluoxetine; Frontal Lobe; Humans; Male; Neuropsy | 1991 |
Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment.
Topics: Adolescent; Age Factors; Child; Clinical Trials as Topic; Double-Blind Method; Female; Fluoxetine; H | 1991 |
Three cases of paraphilias responsive to fluoxetine treatment.
Topics: Adult; Exhibitionism; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Paraphilic Disorders; | 1991 |
Treatment of pathological jealousy by fluoxetine.
Topics: Adult; Delusions; Female; Fluoxetine; Humans; Jealousy; Obsessive-Compulsive Disorder | 1991 |
Fluoxetine in anorexia nervosa.
Topics: Anorexia Nervosa; Depressive Disorder; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder | 1991 |
Neurologic soft signs in obsessive-compulsive disorder.
Topics: Adult; Anxiety Disorders; Central Nervous System Diseases; Clomipramine; Clonidine; Depressive Disor | 1991 |
Fluoxetine and bleeding in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Aged; Female; Fluoxetine; Hemorrhage; Humans; Middle Aged; Obsessive-Compulsive D | 1991 |
Fluoxetine treatment of voyeurism.
Topics: Adult; Drug Administration Schedule; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Voyeur | 1991 |
Efficacy of long-term fluoxetine treatment of obsessive-compulsive disorder.
Topics: Body Weight; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Time Factors | 1990 |
Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment.
Topics: Adult; Clomipramine; Drug Administration Schedule; Drug Therapy, Combination; Female; Fenfluramine; | 1990 |
Treatment of depersonalization with serotonin reuptake blockers.
Topics: Adolescent; Adult; Clomipramine; Depersonalization; Dose-Response Relationship, Drug; Female; Fluoxe | 1990 |
Transient SIADH associated with fluoxetine.
Topics: Depressive Disorder; Fluoxetine; Humans; Inappropriate ADH Syndrome; Male; Middle Aged; Obsessive-Co | 1990 |
The pharmacotherapy of moral or religious scrupulosity.
Topics: Adolescent; Adult; Aged; Catholicism; Clomipramine; Drug Therapy, Combination; Female; Fluoxetine; H | 1990 |
Paradoxical reaction to buspirone augmentation of fluoxetine.
Topics: Adult; Buspirone; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Humans; Impuls | 1990 |
Combining fluoxetine with desipramine.
Topics: Adolescent; Desipramine; Drug Interactions; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorde | 1990 |
Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: preliminary clinical experience.
Topics: Adolescent; Akathisia, Drug-Induced; Child; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive D | 1990 |
Fluoxetine for the treatment of compulsive facial picking.
Topics: Adult; Disruptive, Impulse Control, and Conduct Disorders; Female; Fluoxetine; Humans; Obsessive-Com | 1990 |
Fluoxetine for adolescents with obsessive-compulsive disorder.
Topics: Adolescent; Child; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder | 1990 |
Fluoxetine treatment of exhibitionism.
Topics: Adult; Exhibitionism; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Paraphilic Disorders | 1990 |
Fluoxetine treatment of borderline mentally retarded adults with obsessive-compulsive disorder.
Topics: Adult; Female; Fluoxetine; Humans; Intellectual Disability; Male; Obsessive-Compulsive Disorder; She | 1990 |
Fluoxetine-induced akathisia in male OCD patients.
Topics: Akathisia, Drug-Induced; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Sex Factor | 1990 |
Successful fluoxetine treatment of pathologic jealousy.
Topics: Adult; Drug Administration Schedule; Fluoxetine; Humans; Jealousy; Male; Obsessive-Compulsive Disord | 1990 |
Suicidal preoccupation during fluoxetine treatment.
Topics: Fluoxetine; Humans; Obsessive-Compulsive Disorder; Serotonin; Suicide | 1990 |
Obsessive-compulsive disorder.
Topics: Adult; Behavior Therapy; Clomipramine; Diagnosis, Differential; Female; Fluoxetine; Fluvoxamine; Hum | 1989 |
Obsessive compulsive disorder.
Topics: Behavior Therapy; Clomipramine; Fluoxetine; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Oxim | 1989 |
Panic attack precipitated by fluoxetine.
Topics: Adult; Alprazolam; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Panic Disorder; Psychiat | 1989 |
Fluoxetine-induced akathisia: clinical and theoretical implications.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Depressive Disorder; Dopamine; Dyskinesia, Drug-Induced; | 1989 |
Trazodone-fluoxetine combination for treatment of obsessive-compulsive disorder.
Topics: Adult; Drug Therapy, Combination; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Trazodone | 1989 |
Drug response assessed by the Modified Maudsley Obsessive-Compulsive Inventory.
Topics: Adult; Clomipramine; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Psychiatric St | 1989 |
Fluoxetine and anorgasmia.
Topics: Adult; Depressive Disorder; Female; Fluoxetine; Humans; Male; Middle Aged; Obsessive-Compulsive Diso | 1989 |
Open trial of fluoxetine in obsessive-compulsive disorder.
Topics: Adult; Depression; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Personality Test | 1989 |
Fluoxetine overdose in an adolescent.
Topics: Adolescent; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Suicide, Attempted | 1989 |
Fluoxetine treatment of obsessive compulsive disorder.
Topics: Adult; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder | 1989 |
Fluoxetine for depression.
Topics: Antidepressive Agents, Tricyclic; Depressive Disorder; Fluoxetine; Humans; Obesity; Obsessive-Compul | 1988 |
Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports.
Topics: Adult; Akathisia, Drug-Induced; Arrhythmias, Cardiac; Drug Interactions; Female; Fluoxetine; Humans; | 1986 |
Obsessive disorder with self-mutilation: a subgroup responsive to pharmacotherapy.
Topics: Adult; Clomipramine; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Propylamines; | 1987 |
A second case of mania associated with fluoxetine.
Topics: Adult; Bipolar Disorder; Depressive Disorder; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorde | 1985 |
Antiobsessive effect of fluoxetine.
Topics: Clomipramine; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Propylamines; Psychiatric Status Ra | 1985 |
Fluoxetine in the treatment of obsessive compulsive disorder.
Topics: Adult; Female; Fluoxetine; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Propylamines; P | 1985 |